The Index
519 dossiers
A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.
Bullish4 names· avg TR 16 | ||||||||
T | The chokepoint that captures the foundry + CoWoS-packaging rent for the ENTIRE AI complex (NVIDIA, AMD, Broadcom, Apple all depend on it), trading at ~22× forward — BELOW every customer it supplies — with the only real risk exogenous (Taiwan geopolitics, the source of the discount). The cleanest, highest-quality, lowest-multiple way to own AI infrastructure. BULLISH / HIGH / 1Y+. | BullishHigh | 22 | |||||
| Captures the LARGEST slice of the HBM scarcity rent (~62% share, ~2/3 of NVIDIA's HBM4, 72% op margin, ~61% ROE) yet is valued like a Korean memory-cyclical (~6–9× forward) — and management's own $14B US listing is an explicit re-rating bet. Best HBM rent-capture in the cluster. BULLISH / MEDIUM-HIGH / 1Y. | BullishMed | |||||||
| Best franchise in AI infrastructure at an undemanding 21x forward — but revenue quality is migrating to the balance sheet (54% customer concentration + a circular-financing loop), so this is quality-at-fair-price, not mispriced growth. BULLISH / MEDIUM / 1Y. | BullishMed | 12 | ||||||
| "NEUTRAL / WATCHING — the business genuinely transformed (clean books, $22B prepaid take-or-pay raising the floor, data-center 61% of revenue), but at ~$1,133 (~8x PEAK EPS, upside capped at peak-price SCA ceilings, ~60% of revenue spot-exposed to CXMT, EV/EBITDA premium to the HBM leader) the bull case is in the price. Quality confirmed; entry unattractive — own the dips, not the rip. Diverges from the prior web-only dossier's BULLISH on the ENTRY, not the business." | BullishMed | |||||||
Watching1 name· avg TR 12 | ||||||||
| The most dangerous competitor bulls underestimate — the named beneficiary of NVIDIA's own inference-share vulnerability, growing AI +143% — but priced at a PREMIUM to NVIDIA (45× vs 30× EV/EBITDA) on one-third the ROE, with lower earnings quality (acquisition-amortization add-backs, $64B debt) and the same hyperscaler concentration. The most expensive, lowest-quality way to play the custom-silicon thesis. NEUTRAL / WATCHING / MEDIUM. | ||||||||
No call482 names· avg TR 4 | ||||||||
| The #1 knee/hip implant franchise priced for failure (~12x fwd EPS) — but it is the value trap until it proves organic growth can clear 3% without the Paragon/Monogram M&A crutch and stops losing the robotics war to Mako. Cheap is the thesis and the warning. | — | 8 | ||||||
| 18 |
| 12 |
| The picks-and-shovels king of the AI buildout — #1 in optical transceivers with >50% of Nvidia's wallet and the lowest forward P/E of any peer — but it is a margin-taker squeezed between US chip suppliers it cannot displace (Broadcom/Marvell DSP, Lumentum/Coherent EML) and Nvidia's own CPO/in-house ambitions, and the price already discounts flawless 1.6T execution. | — | 1 |
| A vertically-integrated battery-metals champion now earning peak-cycle profits off a DRC-driven cobalt spike it does not control — the equity is cheap (~12x) precisely because the market correctly senses the earnings are borrowed from policy, not durable from moat. | — | 8 |
| A cheap, well-run AIDC compounder mis-tagged "robotics" — it just SOLD its robots; the real bet is whether ~4% organic hardware growth + buybacks + a tariff-refund kicker re-rates a 13x stub the Street already targets at $330. | — | 8 |
| A de-risked balance sheet ($2.3B cash, two partnered Phase-3 obesity assets) wrapped around a lead drug the market has already judged "undifferentiated" — the bet is that tolerability-led amylin still wins share in a >$150B market, not that petrelintide out-loses Lilly/Novo. Watchlist, not conviction-long, until ZUPREME-2 (H2'26) and a Phase-3 design tell us whether 10.7% mono + combo upside is the real story. | — | 8 |
| A blue-chip-pedigree laser-source play (Columbia photonics royalty + ex-Broadcom CPO lead, NVIDIA on the cap table) that is correctly positioned as a picks-and-shovels supplier to the optical-interconnect buildout rather than a CPO competitor — but is ~10-40x under-capitalized vs Ayar/Lightmatter/Celestial and has zero disclosed design wins, so it is a WATCH-grade private until a named hyperscaler qualification or a strategic (NVIDIA/Broadcom) laser-supply deal converts pedigree into revenue. | — | 8 |
| A near-breakeven Chinese smart-EV OEM whose margin (GM 18.9% FY25, ~20% Q1'26) and a high-margin VW software-licensing annuity are real — but FY26 volume has rolled over (-22.6% YTD), and the IRON/eVTOL/robotaxi "embodied-AI" optionality the bulls pay for is unproven cash-burn; long the software+margin inflection at a 52-week-low multiple, but only if the GX/new-model cycle re-accelerates deliveries by 2H26. | — | 1 |
| A pre-revenue photonic moonshot priced like a product company — ~711x EV/sales on $4.6M revenue, ~3yr runway, a real Nature-grade tech lead but a 12-logical-qubit reality vs a 2029-30 promise, and a 293.6M-share resale overhang that already cut it ~65% in a day. Genuine optionality, dilution-and-timeline-risk valuation. WATCHING, not owning. | — | 8 |
X | A frontier lab fused into Musk's compute-and-distribution empire — Grok is a fast-following #4 model bankrolled by a $30B/yr capex furnace; the real instrument is now SpaceX equity at a $1.25T mark, not a standalone xAI bet. | — | 1 |
| A real, cash-generating neocloud retrofitter trading at ~18x trailing sales on a single $865M Nscale contract and a still-71%-Bit-Digital-controlled cap table — the build is genuine, but the multiple already prices the NC-1 inflection that hasn't happened yet. | — | 1 |
| A re-rated electrical/datacom distributor riding a genuine 70%-growth data-center wedge — but the multiple now prices the AI-capex story while the underlying engine is still a ~7% EBITDA-margin, ~10% ROIC, 3.4x-levered cyclical that bled cash in 2025. Quality WATCH, not a price-chase. | — | 8 |
| A de-risked regulated-utility play on the data-center power buildout — the PSCW's April-2026 verbal approval of the VLC/Bespoke tariffs converts a $37.5B capex plan into a rate-base annuity, but at ~20x forward EPS the re-rating is mostly priced and the upside now lives in 2028 acceleration, not the multiple. | — | 0 |
| A merchant-power balance sheet wearing a regulated-utility's contracted growth — long-dated nuclear PPAs to AWS/Meta de-risk the AI-demand story, but the GAAP P&L is hostage to hedge mark-to-market and the equity carries ~3.4x the net debt of Constellation. Cheapest large-cap way to own the data-center power trade if (and only if) ERCOT/PJM load growth shows up; bull at ~10x forward EBITDA, but leverage + commodity beta make it the high-volatility expression, not the safe one. | — | 8 |
| A real low-margin cyclical recovery that the tape has detonated into a ~400%/3-month, 13%-short-squeeze re-rate to ~$52 — and management just sold 15M shares at $50 into it, the loudest tell that fair value sits far below the print. BEARISH the price, BULLISH the cycle; WATCHING for the squeeze to unwind. | — | 8 |
V | A toll-road compounder mispriced as a disruption victim — 60%+ margins and 16% top-line growth are intact while the market discounts a debit antitrust loss and a stablecoin bypass that the numbers (cross-border +17%, $7B stablecoin run-rate is on-network, not against it) do not yet support; structurally BULLISH, but the DOJ debit case and the interchange settlement's final approval are real, dateable downside. | — | 0 |
| "A pre-revenue going-concern burning ~$90M/qtr toward a binary Q4-2026 Delta restart, funded by a death-spiral of ATM dilution and debt-paid-in-stock; the product may fly, the equity is structurally engineered to be diluted to nothing — BEARISH on the equity, WATCH the flight test as a trade-only event." | — | 8 |
| The best obesity asset not yet owned by Big Pharma — but the market has already priced in a near-perfect Phase 3, leaving a binary 2027 readout where the upside is a takeout and the downside is a trap-door; SC maintenance data in Q3 2026 is the next real tell. | — | 1 |
| A leveraged GEO incumbent that survived a flagship-satellite catastrophe and is being re-rated as a defense + spectrum (D2D) play — but the equity has already run +955% off the lows and now prices the optionality, not the still-loss-making, structurally-Starlink-threatened core. | — | 8 |
| Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket. | — | 1 |
| The default arms dealer of the AI buildout — a real moat compounding a $15B backlog into 30% organic growth, but priced at 82x for perfection while insiders sell 65:0 and EMEA orders are already cracking. | — | 0 |
| A cash-gushing CF monopoly priced for a successful four-engine diversification (pain, renal, gene therapy, diabetes) that is, so far, only one-third proven — own the moat, underwrite the pipeline at a discount. | — | 1 |
| A rare profitable, debt-free genomic-dx compounder (FY25 16% rev growth, $126M FCF) — but the stock has doubled into a 6.5x-sales / ~30x-FCF valuation just as Natera's FDA-approved Signatera CDx occupies the exact MIBC beachhead TrueMRD is launching into. Quality business, priced for flawless MRD execution it has not yet proven. WATCHING; would buy a reimbursement/launch-driven pullback under ~$40. | — | 8 |
| A fortress-margin vertical-SaaS monopoly trading at a growth-stock funeral price (~20x forward EPS, near 52-wk lows) because the market is pricing a Salesforce-Agentforce CRM war that threatens the contested ~40% (Commercial) while ignoring the defensible, faster-growing ~60% (R&D/Quality); BULLISH at $153 on a 1–3Y view, but the CRM-migration-to-2030 is a real, watchable execution overhang — not a phantom. | — | 1 |
| A pre-revenue mine-to-magnet roll-up that the U.S. government has chosen to underwrite — own the policy-protected build-out, not the ~240x-sales price; the bet is execution-by-2027, and the kill-switch is a single slipped milestone meeting a $5.5B valuation with $23M of revenue. | — | 1 |
| A leveraged, no-reserves bet on the U.S. uranium-independence trade dressed as an operating miner — production is real but trivial, the share count is the business model, and at ~300x sales you are paying for the spot price and the policy narrative, not the P&L. | — | 1 |
| A negative-book-equity Solana levered fund wearing a consumer-products costume; with the stock at ~0.7x NAV, ~$185M of SOL-repayable convert/credit debt against a ~$165M treasury, and converts struck 4–5x above the share price, the equity is a deep-out-of-the-money call on SOL where bondholders own the first ~52% of the coins — BEARISH on the equity, structurally distinct from "owning SOL." | — | 8 |
| "UNINVESTABLE — DEAD COMPANY. Unity dissolved (Delaware cert. filed 26 Sep 2025), delisted from Nasdaq (16 Aug 2025, now OTC Pink as UNBX), board cut 8→1, and the board itself expects ZERO distribution to shareholders. The senolytic science had a real signal (BEHOLD 48-wk durability, NEJM Evidence) but the lead asset UBX1325 missed the ASPIRE Phase 2b primary endpoint (non-inferiority met only at 88% CI vs the >90% bar) with ~$17M cash and no partner — the textbook single-asset, undercapitalised biotech death spiral. The only residual is a possible UBX1325 IP sale, on which the landlord holds a 25% monetisation clawback. Equity = a confirmed zero; the value here is the cautionary lesson, not a position." | — | 8 |
| The only profitable humanoid maker and #1 by volume — but the float is a Shanghai-only embodied-AI bet whose revenue is 74% lab demos, not labor replacement, and whose Western TAM is being legislated to zero. | — | 1 |
| A $2.8B equity wafer balanced on an $11B junk-rated debt tower — the whole thesis is whether Kinetic fiber penetration ramps EBITDA fast enough to delever before the 2028–2031 maturities, and the market has already paid up for that bet. | — | 1 |
| A ~$1.1B market cap wrapped around a ~$40M-revenue, loss-making smelter — the only US vertically-integrated antimony producer, priced almost entirely on a back-end-loaded $125M federal-ramp promise from a serially-promotional CEO; own the antimony scarcity story, but the equity is a momentum/policy option, not a value asset. | — | 1 |
| A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding. | — | 0 |
| The world's #1 vertically-integrated TiO2 producer is a high-quality asset trapped under an 11.1x-levered balance sheet in the worst pigment down-cycle in a decade — the equity is a leveraged call option on a 2027 cyclical recovery (plus a free rare-earth lottery ticket), not an investment, and the 2029 maturity wall is the clock. | — | 1 |
| A mispriced compounder — the AEC-software pivot is working (ARR +13%, guide raised) but a restatement-and-material-weakness overhang has cut the stock ~37% YTD to ~14x forward EPS, the cheapest in its peer set; the gap closes once controls are remediated. BULLISH (governance-gated). | — | 8 |
| A best-in-class HVAC compounder (36% ROE, record $10.7B backlog, +24% organic bookings) bolting a genuine data-center cooling franchise onto its core — but priced for it at ~31x forward, with a fresh price-fixing class action as the cheap-tail risk the market is shrugging off. Quality is real; the entry multiple is the whole debate. | — | 8 |
| A fortress-balance-sheet specialty-analog foundry that has been repriced overnight from a $45 cyclical into a $250 AI-silicon-photonics growth story — the operational inflection is real (Q1'26 op-profit +96%, $1.3B of 2027 SiPho contracts, $290M prepaid), but at ~66x forward EPS the stock already discounts most of the 2028 model, and a fresh GlobalFoundries patent-injunction suit at the ITC is an asymmetric, under-priced tail risk. Long the business, cautious on the multiple. | — | 8 |
| The toll-road of science — a fortress compounder you buy for the next decade, not the next quarter; at ~18x forward EPS it is as cheap as it has been in years precisely because organic growth is stuck at ~2% and the GAAP/adjusted gap is widening, so the bet is that PPI productivity + biopharma normalization + Clario/Olink revenue synergies re-accelerate organic to mid-single-digits before the multiple has to. | — | 1 |
| Best analog franchise on Earth, mid-cycle, fully priced — the FCF-inflection thesis is now consensus at ~40x forward and above Street targets; you're buying quality at a cyclical-optimism peak, with China share-loss the under-priced tail. WATCHING, not chasing. | — | 8 |
| A profitable EV maker priced as a solved-autonomy robotics company — the car business is shrinking, the GAAP profit prop (reg credits) is going to zero, and the entire ~190x multiple now rents on robotaxi + Optimus execution that is real but years behind the price. | — | 1 |
| "Already over — Merck closed its $53.00/sh ($6.7B) all-cash buyout of TERN on 5-May-2026 for the CML asset TERN-701 (the obesity bet had already failed); the security is delisted, the spread is gone, and there is nothing left to trade. Coverage value is now the post-mortem, not a position." | — | 8 |
| A coal-plant bitcoin miner that re-priced itself into a $14B "AI landlord" by renting power to a venture-stage neocloud — the equity is a levered call on Fluidstack actually paying, with Google's $3.2B backstop the only thing standing between the multiple and zero. | — | 1 |
| The pure-play picks-and-shovels winner of AI-chip test, printing a vertical Q1'26 (+87%, $2.53 EPS) — but the stock fell ~14% on it because Q2 guidance steps DOWN sequentially and a ~54x P/E prices permanent acceleration; great business, demanding price, cyclical tape. NEUTRAL/WATCHING into the next print. | — | 8 |
| A real, fast-growing oncology-data + diagnostics franchise wrapped in an "AI" narrative it can't yet monetize — own the genomics flywheel, but the round-trip-flavored deals, 30-vote founder, and a CEO famous for cashing out cap the multiple until cash flow turns. | — | 1 |
| A serially-acquiring imaging-and-defense-electronics compounder dressed up under a "robotics" tag — high-quality, defense-levered, ~27x forward earnings with only mid-single-digit organic growth; quality is real, the margin of safety is not. NEUTRAL/WATCHING pending an organic-growth re-acceleration or a multiple reset. | — | 8 |
| A clean-safety, single-asset Rett gene-therapy bet that just de-risked into a one-binary stock — H1'27 6-month pivotal interim + FDA BLA feedback is the entire thesis; an AveXis-grade operator and a competitor's patient death make the asymmetry real, but at a ~$1.8B cap on zero revenue the bear case is "single-trial, single-indication, dilution-funded." | — | 8 |
| A small-float nuclear-and-gas IPP that turned one AWS contract into a re-rating; the moat is the irreplaceable 2.5 GW Susquehanna campus, the risk is that the price already capitalizes a decade of PJM scarcity and premium PPAs that policy can cap. | — | 1 |
| Best-in-class EDA franchise temporarily wearing an Ansys-debt-and-amortization disguise — the GAAP "collapse" is accounting, not the business; the real risk is paying ~35x forward for a name whose Design-IP leg is structurally cracked and whose synergy math doesn't pay until FY2028. | — | 8 |
| The safest, most surgically scalable path into the brain and the only BCI Apple made a native input — but it bet the company on "good enough" 16-electrode bandwidth, and its own third-gen "whole-brain" pivot is a confession that the moat it is famous for may be the ceiling it has to escape. | — | 1 |
| A genuinely differentiated case-handling robotics moat wrapped around an ungovernable accounting-and-concentration core — adverse ICFR opinion + active SEC whistleblower probe + >90% Walmart revenue means the multiple is pricing a clean compounder that the filings say does not yet exist. | — | 1 |
| A real AI-server demand engine (sold-out Blackwell, $39B order book, best-in-class DLC liquid cooling) wrapped in the worst governance dossier in large-cap tech — a co-founder/director under federal export-control indictment, still-unremediated SOX material weaknesses, ~10% gross margins half of Dell's, and a freshly-printed $7B dilutive raise. The business works; the trust does not. WATCHING, not ownable, until the forensic overhang resolves. | — | 1 |
| A consolidating monopolist on a leveraged treadmill — RUN's GAAP "profit" is an HLBV mirage, but the OBBBA's asymmetric kill of 25D (not 48E) hands the TPO leader the residential market it can't yet profitably finance; the bet is whether ~$15B of non-recourse debt rolls before rates or a securitization-market hiccup forces a dilutive reset. | — | 1 |
| A ¥4.4T-revenue diversified Japanese industrial that the market has belatedly re-rated as an AI-optical play — correctly, because Infocommunications (≈6% of revenue) drove ~59% of FY2025 group operating-profit growth and Sumitomo owns ~50% of the global InP substrate chokepoint; but ~57% of revenue is still low-single-digit-margin auto wiring harness, so after a +314% year at ~25x earnings the easy money is made and the bull case now requires the optical mix to keep compounding into a structurally low-margin base. | — | 8 |
| A best-in-class MedTech compounder whose 8-9.5% organic engine is intact, but at ~20x forward EPS the stock already prices the cyber-attack recovery as a formality — the bet is that a $375M Q1 air-pocket is timing, not a dent in the franchise. | — | 0 |
| Best-in-class *oral* GLP-1 efficacy in the wrong race — Structure has a genuine #2 asset and a fortress balance sheet, but Lilly's orforglipron is already approved (Foundayo, Apr 2026) and Structure's Phase 3 only *starts* Q3 2026, so the bet is whether a 2.9B-cap, ~2030-launch latecomer can carve share against the most powerful franchise in pharma. WATCHING, not yet a position. | — | 1 |
| A levered, perpetual-dividend-funded bitcoin holding company whose entire accretion engine — issue stock above NAV, buy BTC — has inverted to a ~0.85x discount, so it is now SELLING bitcoin to pay an ~$0.9B/yr preferred coupon; bullish only as a bitcoin call, bearish as a structure, and the discount is the tell. | — | 1 |
| A debt-free razor-and-blades additive-manufacturing OEM trading at ~0.9x EV/sales — the printers stopped selling but the $249M consumables annuity is intact; a real option on the defense/aerospace reflation and PE-led (Fortissimo) consolidation, but you are paid to wait through a still-shrinking, still-GAAP-lossmaking core. | — | 8 |
| A one-asset, binary bet on a genuinely best-in-class disease-modifying Dravet drug whose pivotal read-out (mid-2027) lands inside a fully-funded runway — own it for the read-out, but size it like the 50/50 single-trial event it is. | — | 1 |
| The only credible bet on FULL (both-stages) reuse besides SpaceX — a metallurgy/physics moat the others ducked — but it is a single-vehicle, zero-revenue, zero-flights company whose entire value is gated on one un-flown second stage surviving reentry; WATCHING, not investable, until Nova reaches orbit and the upper stage comes home intact. | — | 1 |
| A great business priced as a perpetual-motion machine — STRL is the highest-margin pure-play picks-and-shovels name on the AI/data-center buildout (E-Infra 60%+ of revenue, 23%+ segment margins, 2.1x book-to-burn, EPS up ~5x in three years), but at ~80x trailing / ~50x forward and ~4x intrinsic on a deeply cyclical, single-theme, customer-concentrated contractor, the quality is real and the price already capitalizes a flawless decade. WATCHING, not chasing — the dip is the trade, not the breakout. | — | 8 |
| A 30-year never-profitable robotic-navigation company that finally owns its full stack (GenesisX robot + MAGiC catheter) and is one H2 manufacturing ramp away from the razor-and-blade flywheel turning — a binary execution call where the Street's $4+ targets price the ramp as a near-certainty the $6.3M Q1 print does not yet support. | — | 1 |
| A real software-margin turnaround stapled to a ~$332M net-debt stack the ~$10–15M-EBITDA business cannot service from cash — the equity is a ~$67M option on refinancing, not on the operations. | — | 8 |
| Best-in-class low-cost EAF compounder riding a tariff-fattened spread into a stock that already prices the good news — the edge is the aluminum option and through-cycle discipline, not the current multiple. | — | 1 |
| Not a tools company anymore — a sub-NAV cash shell mid-conversion into Treeline's oncology pipeline; the only edge is the deal-spread between ~$325M market cap and the ~$460M net cash being delivered, and that spread is a bet on Bilenker's KRAS/BCL6 readouts, not on CyTOF. | — | 1 |
| China's only fully-invasive (intracortical) BCI in the clinic and the best-capitalized BCI name in the country — a credible Neuralink analogue whose real near-term value is the closed-loop DBS line attacking a proven multi-billion Parkinson's/epilepsy market, not the 256-channel BMI moonshot; the bet is "does the uFINE ultra-flexible electrode hold up in a 40-patient registration trial and does NMPA's Green Channel actually compress the path to 2028 revenue," on a name with zero public financials and an undisclosed valuation. | — | 8 |
| A high-quality HVAC compounder that the market has correctly repriced as a data-center cooling play — own the operations, but at ~28x forward EPS / ~25x EBITDA the easy re-rate is done; the next leg is execution on the $700M capacity build, not multiple expansion. | — | 8 |
S Spire Globalcatalyst in 42d | A post-divestiture, debt-free space-data pure-play whose entire FY25 "profit" was a one-time Kpler gain — underneath it, continuing-ops revenue is still shrinking double-digits and management is guiding to a deeper FY26 cash loss, all under a live SEC subpoena and unremediated material weaknesses. Real backlog and a credible RF/weather-data thesis, but the tape is a serial-dilution machine priced at ~9x sales. WATCHING, not owning, until burn inflects and the SEC overhang clears. | — | 8 |
| A genuine launch-and-connectivity monopoly wrapped inside an unprofitable $2T+ aspiration stock — Starlink is the real business, but at ~110x sales the market is paying for Mars, orbital AI data centers, and a $60B Cursor bet that aren't earnings yet. | — | 1 |
| The world's lowest-cost, longest-reserve, highest-margin copper pure-play — a generational asset wrapped in a Sell-rated price and 88.9% Grupo Mexico control; you want the orebody, not the multiple, and the market agrees. | — | 1 |
| A regulated-utility levered call on the Georgia data-center build-out — the cleanest large-cap way to own AI power demand, but priced as if the affordability politics and equity dilution won't bite; own the growth, respect the ~24x multiple. | — | 1 |
| A real turnaround that has already been paid for — six straight quarters of margin repair and the return to positive operating cash flow are genuine, but at ~$60 the stock prices in a clean, AMPTC-independent recovery the filings explicitly say does not yet exist (ex-45X credits, SolarEdge is still gross-loss-making), so the asymmetry from here is poor. | — | 1 |
| A profitable, fast-growing digital bank mispriced as a crypto name and now mispriced again by fear — but the entire bull/bear hinges on one binary question the market cannot yet resolve: are the +$2.0B of fair-value loan marks real, or is Muddy Waters right? | — | 1 |
| SKYT is no longer a foundry — it is an IonQ deal-stub trading $38.40 vs a $35.00 closed-vote merger value, i.e. a +10% premium that is pure leveraged FTC-cleared bet on IonQ rallying past $60.13; the standalone foundry (43% Infineon, negative op cash flow, $22M cash) is the break-case floor, not the thesis. | — | 1 |
| A structurally sub-scale #6 battery maker whose survival now rests on a US-policy bet that just inverted — the Ford anchor is gone, EV demand cratered, and the entire growth pivot (ESS/LFP) is a margin-thin race into China's home turf; only the SK Group balance sheet keeps it solvent, and there is no tradeable security to express a view on. | — | 1 |
| The leading robot-foundation-model pure-play by capital and strategic syndicate, but its $14B mark prices a software-layer monopoly that the Foxconn/Blackwell line has yet to prove and that Physical Intelligence + NVIDIA's own GR00T are both armed to contest. | — | 1 |
| Real structural node in the scarce InP-laser chokepoint, but a ~$33M-revenue, going-concern-flagged, restatement-tainted micro-cap is now priced at a ~SEK 29bn / ~31x P/S momentum bubble — the technology is investable, the stock at this price is not. BEARISH on the equity, WATCH the business. | — | 8 |
| The MEMS-timing monopolist is being bid as if it has already won the AI clock — at ~35x sales and ~85x forward earnings, a flawless +88% quarter and the transformational Renesas deal are not just priced in, they are required. | — | 1 |
| A profitable biosimulation pure-play that the public market broke (Pro-ficiency wrote off ~$72M of a $100M deal, growth fell to single digits) — and is now exiting via a $18.50/sh all-cash Altaris take-private. The fundamental thesis is moot; the only live question is deal-closes-vs-breaks, and this closes (board-unanimous, 16% founder block locked, Q4-2026 close). Merger-arb, not a growth bet. | — | 1 |
| This is no longer a chip stock — it's a near-closed merger-arb. TI buys SLAB for $231 cash; HSR cleared and shareholders approved, only China SAMR left, ~6% gross spread to close in 1H2027. The trade is deal certainty, not IoT growth. | — | 1 |
| A ~$3M-revenue, going-concern-adjacent micro-cap whose stock is a Golden Dome / lunar-data narrative trading at >70x sales, kept alive by serial sub-$2 raises (15.96M→80.76M shares in 18 months) and ~half its revenue self-dealt from the CEO's own private company — the equity is a momentum vehicle, not a business; BEARISH on fundamentals, but un-shortable on borrow/squeeze risk. | — | 8 |
| A re-accelerating solar-EBOS niche-monopolist (FY26 guided +30%, record $758M backlog, IP win pending) trading at ~27x fwd P/E on a near-empty balance sheet ($1.9M cash, revolver 91% drawn) — the growth is real but the equity is priced for it and the funding runway is the actual risk, not the (now-settled) shrinkback overhang. | — | 1 |
| A levered, sub-NAV Ethereum proxy run by the best operators in the trade — own the discount-closing buyback, not the "treasury premium" that already died; the bet is ETH plus a 0.83x→1.0x mNAV mean-reversion, fighting a 95% drawdown and a structurally bigger rival. | — | 1 |
| A genuine deleveraging turnaround (9.0x→~1.6x net leverage) that has tripled on AI-datacenter optionality — but the stock now prices that optionality at ~62x forward earnings while Credo owns ~88% of the very AEC market Semtech is fighting to enter; the moat is real in TVS/LoRa, not yet proven in datacenter interconnect. WATCHING, not chasing. | — | 8 |
| A regulated T&D utility wearing a busted-LNG-conglomerate's discount — the KKR/Ecogas sale converts Sempra into a ~pure US wires play levered to the single best load-growth story in America (Oncor's 200+ GW data-center queue), and at ~18.5x forward for 7–9% EPS growth + 3% yield it is the cheapest way to own the AI-transmission build-out. The fork is execution, not story: a Baa3/BBB- balance sheet on negative outlook funding a $65B plan with deeply negative FCF, and a California rate base that just taught shareholders (Feb 2025, −18%) it can reprice them at will. | — | 8 |
| The first BCI company with a *shipping product and real efficacy* — PRIMA gives blind dry-AMD patients fluent reading (25.5 ETDRS letters, NEJM) — wrapped around a moonshot biohybrid lab still in mice; you are buying a near-term medical-device cash engine that is funding a 10-year cortical bet, at a $1.5B mark that is cheap vs Neuralink's $9B and rich vs the device's standalone medtech comps. | — | 8 |
| A genuinely moated physics-based drug-design platform stapled to a cash-burning pipeline it can no longer afford to develop — the software is finally being valued like software (2.5x EV/sales), and the hosted transition is depressing the very revenue line the market punishes hardest. Buy the platform, not the headline P&L; the re-rate needs ACV reacceleration + one partnered pipeline win, not a clinical miracle. | — | 1 |
| A best-in-class tower compounder having its worst year in a decade — 2026 AFFO/share is guided DOWN on DISH+Oi+Sprint churn and refinancing, and the M&A premium has fully bled out of the stock; structurally bullish for 3Y, but no rush at 15.5x AFFO with the churn cliff still in front of it. | — | 1 |
| A $20M-revenue EO manufacturer trading like a $1B growth story on a 200% YTD re-rate — the cost-per-satellite edge and Tether-backed balance sheet are real, but the price already discounts a Merlin success that hasn't launched, and three customers are half the revenue. | — | 1 |
| A de-risked-but-not-cured value/event play — the AAVrh74 gene-therapy franchise is structurally impaired (3 deaths, label cut to ambulatory, ELEVIDYS run-rate halved), trading at ~0.8x sales because the market prices terminal decline; the only thing that re-rates it is the Arrowhead siRNA pipeline working, and that is a 2027-28 question, not a 2026 one. WATCHING, not yet a position. | — | 8 |
| A bankrupt platform pioneer whose science (STAC-BBB capsid) outlived its balance sheet — Chapter 11 filed 23 Jun 2026, assets being sold to Lilly + Astellas for ~$75M cash floor against ~$79M liabilities plus a $30M super-priority DIP; the common (now SGMOQ, ~$0.15) is a near-certain zero. AVOID/short the equity; the only thing left to trade is the 363 auction, and that value accrues to creditors, not shareholders. | — | 8 |
| World-class robotic hands and the #3 humanoid patent estate on Earth, attached to a balance sheet that already had to sell its best asset (the Apptronik stake) to make payroll — this is an IP carcass walking, far likelier to be acqui-hired or stripped for patents than to IPO independently. | — | 1 |
| A loss-making #9 EV-cell laggard re-rating on an ESS/data-center pivot the market is pricing as a turnaround — the call is whether US grid-storage demand and 2027 solid-state outrun Chinese LFP deflation before the balance sheet (rights issue + Display-stake sale) runs out of runway. | — | 1 |
| The cheapest way to own the memory supercycle — a $63B-net-cash colossus that just clawed back into Nvidia's HBM4 supply chain at ~7x forward earnings, but the market's discount is a verdict on memory cyclicality and Samsung's execution, not a mistake. Bullish on the re-rate; the kill-switch is a 2027 oversupply that turns peak earnings into the top tick. | — | 1 |
| A credible Oxford/Münster silicon-photonics team that pivoted from a losing optical-compute bet to the right one — all-optical circuit switching — and shipped a real 32-port product, but it is a ~£137M-valued, sub-$50M-raised minnow standing in a lane Nvidia, Lumentum and a $4.4B Lightmatter are all paving; WATCHING, not investable, until a named hyperscaler design win proves the silicon-photonic-OCS approach beats incumbent MEMS in production. | — | 8 |
| A de-risked, debt-light gold royalty toll-bridge that just doubled in size via Sandstorm yet trades at a ~7-9x P/E discount to Franco-Nevada and Wheaton — the discount is the thesis, not the warning. | — | 1 |
| A genuine cyclical trough-to-recovery (FY25 → FY26) running into a top-decile valuation — the operational re-rate is real (S&C software margin 35%, data-center demand doubling) but the stock already prices ~$14 of FY27 EPS at 35× forward, so the asymmetry is poor near a 52-week high. WATCHING; buy the next destocking air-pocket, not this print. | — | 8 |
| A genuinely great company and a genuinely terrible price — the only Western full-stack launch+satellite pure-play, compounding at ~50%, but trading at ~64x EV/sales with the entire Neutron thesis still un-flown. Own the business, fade the multiple. | — | 1 |
| Cheapest of the EU big-three on a real ~36% core margin and a 39-year dividend record, priced as if the Ocrevus 2028/29 cliff has no bridge — but it has three (subcut Zunovo conversion, oral-BTK fenebrutinib, and a credible 22.5%-WL obesity option in CT-388); the binary is execution on the bridge, not the moat, so I'd be a patient accumulator below the cliff, not a momentum buyer. | — | 8 |
| A real, cash-generative super-app now valued like a crypto-beta call option — the bull thesis (tokenization + a 27M-customer flywheel) is genuine, but ~37x forward earnings re-prices violently every time the crypto/options trading cycle exhales, and the prediction-markets engine that drove Q1 growth is one adverse court ruling from being switched off. | — | 1 |
| A bitcoin miner whose P&L now swings on the BTC mark, not operations — repricing itself as a 1.7 GW AI/HPC power landlord on the back of one $311M AMD lease and a Starboard-pushed pivot; the ~$10.6B cap is paying for an optionality that is still 95% promise. | — | 1 |
| A $5M-revenue, revenue-SHRINKING robot company trading at ~90x sales is really a $270M cash-box wrapped in a serial-dilution, AI-partnership-hype machine — now under a 10b-5 class action for a Microsoft "partnership" Microsoft denied; the only real value is the cash, and management is burning it while printing stock. | — | 1 |
| A reagents-and-screening compounder trapped in a goodwill cage — durable razor/razorblade franchises and a 40%-ARR software call option, but ~3% organic, ~3% GAAP ROIC, and a China overhang mean the bull case is "self-help re-rating," not growth; cheap on forward EPS (~16x) only because GAAP earnings are a fiction of amortization. | — | 8 |
| A genuine builder's longevity platform de-risking faster than its peers, but the $1.8B mark is a 64% haircut off the $5B it was chasing six months ago — own it only after the August RTR242 readout converts "no tox" into a real biomarker signal, not before. | — | 8 |
| A genuinely differentiated allosteric PI3Kα asset with a clean ~$642M balance sheet and runway to 2029 — but the entire equity is one Phase 3 readout (ReDiscover-2) into a class that just got a $3B Novartis validation and a first-line Roche incumbent; own the science, respect that the market is pricing a win. | — | 1 |
| No longer a rocket startup — an Eric Schmidt-controlled option on Terran R becoming the launch arm of an orbital-AI-datacenter thesis, gated entirely on an unflown late-2026 maiden flight and carrying a stale $4.2B (2021) mark that almost certainly no longer holds. | — | 1 |
| A billionaire-seeded Swiss "hallmarks-of-aging" holdco that quietly went dark — rebranded to Centenara in Sep-2024, lead eye asset terminated, holdco comms silent ~21 months; the ONLY live value driver is a separately-financed Belgian portco (Rejuvenate Biomed RJx-01, Ph2 COPD-sarcopenia, topline end-2026). Un-investable as a private until an IPO path or a single de-risked asset emerges; WATCHING the RJx-01 readout only. | — | 8 |
| A real, accelerating dual-use (space + combat-proven drones) franchise welded onto a still-loss-making, AEI-controlled, serial-dilution SPAC — the business is finally interesting but the cap table and cash burn are doing the pricing; WATCHING, not yet ownable, until the ATM overhang clears and adjusted EBITDA turns. | — | 8 |
| The most-instrumented AI drug-discovery platform with the thinnest clinical proof per dollar burned — one real Phase-2 win (REC-4881/FAP) against a $2.2B accumulated deficit, smart-money exiting (NVIDIA, Mubadala out), and a $1.67B market cap that is now a binary bet on Najat Khan converting platform optionality into a registrational asset before the cash runway forces another raise. | — | 1 |
| A first-mover NGPS tools story whose commercial engine is going backwards (revenue −20% in FY25, −69% in Q1'26 to $258K) while it bets the company on Proteus by end-2026; ~$190M cash funds the bet, but a 69%-Rothberg-controlled sub-$1 microcap with collapsing instrument demand is a binary option, not an investment — WATCHING until Proteus ships and consumable pull-through proves real. | — | 1 |
| A genuine ceramic-separator moat wrapped around a capital-light VW/PowerCo license — but the equity is a $4.4B option on a $130M royalty cheque that has NOT yet been triggered, burning ~$60M/quarter of cash against a binary milestone it does not control. | — | 1 |
Q Quantum Computing Inccatalyst in 43d | A $2.5B market cap on $682K of FY25 revenue — QUBT is a $1.5B treasury wrapped in a photonics R&D lab, sold as a quantum-computing story; the balance sheet is real, the revenue is not, and a securities-fraud class action over the exact gap between the two is unresolved. | — | 1 |
| A shrinking ultra-sensitive-protein tools business (Simoa organic −20% to −36%) using a dilutive all-in spatial-biology acquisition (Akoya) to manufacture headline "growth" — the real bet is whether a 510(k)-pending Alzheimer's blood test can outrun the academic-funding bust before the ~$100M cash buffer forces another raise; near-cash optionality, not a compounder. | — | 8 |
| The purest listed pick-and-shovel on the grid + data-center capex supercycle, with a real labor/scale moat and a record $48.5B backlog — but at ~52x forward EPS / ~31x forward EBITDA the market already pays for flawless execution, so the edge is in buying the volatility, not the multiple. | — | 8 |
| The best-engineered way to lose to PsiQuantum — a genuine deterministic-single-photon moat and real machine sales, capitalized at ~1% of its photonic rivals; a sovereign-Europe call option, not a standalone winner. | — | 8 |
| A licensing-fortified cash machine being paid ~20x forward NOT to lose a $7B Apple leg it is already losing — the rerate only comes if Snapdragon-X PCs + custom data-center silicon replace Apple faster than handsets fade, and the tape (rev −3% YoY, Q3 guide −7%) says it isn't there yet. | — | 1 |
| A cash-generative #2/#3 molecular-diagnostics toolmaker trading at a tools-sector discount (~15x fwd P/E, 4x EV/sales) because its single most profitable franchise — QuantiFERON, ~24% of sales — just lost its US-immigration-testing growth engine and cratered FY26 to +1-2% CER; the stock is a recovery/strategic-options call (it sits ~25% below the 2020 Thermo Fisher takeout it rejected, with two activists on the register), not a growth-compounder bet. | — | 8 |
| The most credible analog-photonic-compute bet in Europe — a vertically-integrated TFLN coprocessor with a real fab, a first paying cloud customer (IONOS) and an ARM-founder-grade board — but at $80M raised it is a seed-stage David swinging at a $4B-valued field (Lightmatter) and a just-acquired peer (Celestial AI → Marvell, $5.5B); WATCHING for IPO-proximity, not yet tradeable. | — | 8 |
| A 90%-regulated New Jersey wires utility wearing a merchant-nuclear data-center costume — you are paid ~17x for a 6–8% regulated compounder, and the AI-power optionality is real but unpriced *and* unproven; own it as a rate-base bond with a free nuclear call option, not as the next Constellation. | — | 1 |
| The best-capitalised, hardest-physics bet in quantum — $4B+ in private + sovereign money betting that silicon-photonic fusion-based computing leapfrogs straight to a million error-corrected qubits by ~2027, with the one fact that matters still unproven (a utility-scale machine running) and a freshly installed operator-CEO signalling the company is now an execution problem, not a science one. | — | 8 |
| A single-asset surgical-robotics razor-and-blade compounding ~30% real procedure growth, deliberately torching its own reported revenue to purge channel-stuffed handpieces and install pricing discipline — the half-off de-rate prices in a demand-saturation fear the procedure data does not yet confirm, and a TAVR-category-builder CEO is the call option the tape is ignoring. | — | 1 |
| A David Liu-pedigreed prime-editing pioneer cornered into a defensive crouch — 25% RIF, founder-CEO out, lead CGD asset demoted to a partnering candidate, going-concern doubt at ~14 months of cash, and an existential Beam IP arbitration over one of its two surviving lead programs. At a ~$537M cap it is a deeply discounted binary call option on 2027 first-in-human liver data; bullish only for risk-seeking capital that can survive a dilution-or-bust 2026. | — | 1 |
| The only FDA-cleared, commercially-shipping cortical BCI — but it is selling a 30-day surgical-monitoring tool, not the chronic implant the $500M valuation is priced on; Medtronic is the real tell, IP overhang from Rapoport's Neuralink past is the real risk. | — | 1 |
| A ~$60M-EV option on the only clinical program that *eliminates* HBV cccDNA — first-in-human biopsy proof is real and the asymmetry is large, but it is a single-asset, going-concern-adjacent micro-cap that must out-cure GSK's already-filed bepirovirsen to matter; binary, not investable as a core. | — | 8 |
| A re-racked pure-US regulated T&D utility levered to a genuine PJM/Kentucky data-center load wave — 10.3% rate-base CAGR and a top-of-range 6–8% EPS algo are real, but at ~19x forward the AI optionality (Blackstone JV, 28 GW PA pipeline) is partly priced and the thesis rests on regulators funding a −$1.4B-FCF capex ramp without an affordability backlash. Quality compounder, not a cheap one. | — | 8 |
| A real GaN/InnoSwitch franchise on a depressed-earnings base that the market has already re-rated +116% YTD onto a 2027-2028 AI-datacenter dream — at ~9x EV/sales and ~54x forward P/E with insiders selling and zero datacenter revenue today, the AI optionality is fully priced; WATCHING for the cyclical-recovery print, not the narrative. | — | 8 |
| A debt-free, cash-rich switchgear specialist that just turned an energy-capex cyclical into an AI-power story — backlog +33%, a record >$400M behind-the-meter data-center order, ROIC >100% — but the stock has already re-rated +296% in a year to ~48x forward P/E, so the bet is now on order durability, not discovery. | — | 8 |
P Pony.aicatalyst in 43d | A genuine top-3 global robotaxi platform finally crossing city-level unit-economics breakeven — but priced for execution it has not yet earned, with a related-party-and-China-permit overhang that the −65% drawdown is screaming about; net-cash floor + founder 540-day lockup make it a WATCHING name to size on proof of fleet-scaling through the permit freeze, not a chase here. | — | 0 |
| A real cost-down turnaround grafted onto a structurally unfinanceable business — burn is halving and the going-concern flag is gone, but the company still funds itself by printing ~450M shares a year; the operations are improving faster than the cap table is being destroyed, but not fast enough to own the equity until EBITDAS-positive (4Q26 promise) is on the tape. | — | 8 |
| A commercial-imagery company that quietly became a sovereign-defense satellite-services contractor — the backlog (+72%) and the Rule-of-40 inflection are real, but a $1.5B ATM on top of ~30x sales means the bet is now whether durable government demand outruns relentless dilution. | — | 1 |
| The category-defining gene-edited nitrogen-fixation company with real revenue (>$100M, 2023) and a tier-1 syndicate — but the product only displaces 15-30% of synthetic N, independent university trials largely fail to find a yield benefit, and it has not raised primary capital since its July-2021 $430M / $2B Series D; WATCHING a private name living off a five-year-old round whose terminal value hinges on an unresolved efficacy question. | — | 0 |
| "A pure-play Arizona regulated utility levered to a genuine data-center demand super-cycle, but priced for execution it hasn't yet earned — the May–Q4 2026 rate case is binary and Arizona's ACC has burned this name before; rate-base growth is real, the multiple isn't cheap, and the regulator is the whole thesis." | — | 8 |
| The strongest research bench in robot learning, priced like a product company while still being a research project — own the index (NVIDIA/data), not this single ticket, until a paying-fleet number or a π1 zero-shot result exists. | — | 1 |
| A 3-engine specialty-hardware roll-up wearing an "AI factory" costume — the AI-systems story (Advanced Computing) is the lowest-margin, most lumpy, most hyperscaler-concentrated leg, and the actual FY26 EPS beat is being driven by a cyclical memory (DRAM/Flash) price spike that the bulls are extrapolating as if it were the AI thesis; own the re-rating only if you trust the Shaikh-led non-hyperscaler pivot to convert before the memory cycle rolls. | — | 0 |
| A debt-free cash machine trading at 7-9x earnings with a 15%-of-float annual buyback — but the buyback is the whole thesis, because branded checkout (the high-margin core) is barely growing, transaction margin dollars are guided flat, the 2027 plan was withdrawn, the CEO was fired, and three securities class actions now allege the prior team hid the checkout slowdown. Deep value if Lores stabilizes checkout; value trap if the take-rate keeps bleeding. NEUTRAL-leaning-bullish on valuation, LOW conviction until checkout inflects. | — | 8 |
| The highest-bandwidth intracortical BCI just put its wireless device in a human brain (17 Jun 2026) — but it is two patients into an EFS, ~3-5 years from revenue, and out-capitalized ~3-4:1 by Neuralink, so the bet is "bandwidth wins the speech-prosthesis category" against a far better-funded field. | — | 1 |
| A premium-cell incumbent being squeezed from below by Chinese LFP scale and above by its own Tesla over-concentration — but the unit now has a genuine second engine (data-center backup, ~80% share) that the parent's 46x-PER stock does not yet price as a battery turnaround. | — | 1 |
| A pre-revenue embodied-AI software story that quietly became a sub-scale defense-weapons roll-up — the only number growing is bought, the core AI product sells one robot to one customer, and the equity is an ATM dilution machine priced for a backlog 10× its trailing revenue. WATCHING / structurally BEARISH on fundamentals; un-investable under MenFem's no-defense mandate. | — | 8 |
| A genuinely great business priced as a perfect one — 85% growth and 60% adjusted margins are real, but ~55x EV/Sales already discounts flawless execution for years, so the asymmetry is to the downside even if the thesis is right. | — | 1 |
| A long-read pure-play with improving razor-and-blade economics and a real cost roadmap, structurally outrun by Oxford Nanopore and pinned under $641M of out-of-the-money 2029/2030 converts it cannot grow into — a cash-discipline turnaround, not yet an investable one. | — | 1 |
| A real long-read/native-modification monopoly inside a structurally hard razor-and-blade model — but the market has stopped paying for "deep tech that takes 10 years"; down 73% from IPO, near 52-week lows, it is a show-me story where 2027 EBITDA breakeven (twice-pushed) is the entire thesis, and the new ex-Danaher CEO either professionalizes the commercial engine or the optionality stays un-priced. | — | 1 |
| A real, accelerating Western digital-lidar franchise (+49% rev, 43% GM, 13 straight up quarters, June-30 NDAA China ban as a structural tailwind) priced like a winner-take-all at ~15x sales while it still burns cash and lives on serial dilution — own the operating turn, not this multiple. | — | 1 |
| A genuinely differentiated all-optical scale-up fabric with a real CEO and a real AMD/ARIA anchor — but a $93.5M micro-cap fighting $1.2B–$4.4B peers and a hyperscaler-backed open-standard tide; the bet is a strategic acqui-buy (à la Marvell/Celestial), not a standalone IPO. | — | 0 |
| The FY26 10-K turns the bull narrative into audited fact and the bear narrative into a footnote you can now read — $67.4B revenue, $638B RPO, but only 12% converts inside a year, −$23.7B FCF, $129.5B debt, a 13% workforce cut, and a $19B post-quarter purchase commitment; good news kept beating and the stock kept falling (~$166, −52% from peak), which is the whole thesis in one line. | — | 8 |
| The open-source pioneer that defined research-grade DIY neurotech — 40,000+ tools into 100+ countries on under ~$4M ever raised — but a hardware-margin lifestyle business whose one venture-scale bet (the $25k Galea XR headset) is chasing a market that hasn't arrived; a beloved category-shaping brand, an acquisition target at best, never a standalone IPO. WATCHING, not investable. | — | 8 |
| The revenue leader that turned into the cash-burn leader — a $1.4T compute book financed against a P&L losing ~$14B a year, where the only question that matters is whether the IPO window opens before the funding treadmill stalls. | — | 1 |
| "World-first non-invasive SCI neuromod with real FDA labels and a science moat — but a €5M-revenue, €42M-loss company whose €9+ analyst targets price an ARC-IM/BCI future that is still years and one funding round away from existing. Option on neurorestoration, not a business yet." | — | 8 |
| A near-monopoly-tier process-control niche (metrology + advanced-packaging inspection) re-accelerating off a FY25 trough into a guided >30% FY26 — but the tape already pays ~47x forward non-GAAP / 12x sales for it, and the out-of-character $710M debt-funded Rigaku stake is the first capital-allocation question mark in a decade. | — | 8 |
| A genuine top-tier Chinese optics merchant (top-3 passive, #9 global components, real InP/SiPh chip + 1.6T/CPO roadmap) trapped behind a 6-year private wrapper — the only tradeable expression today is the STAR-Market IPO it has been "about to file" since 2023; not investable until the S-1 (招股书) lands, and the coverage ticker 0877.HK is the WRONG company. | — | 0 |
| A high-quality, net-cash subsea-services compounder whose 2025 GAAP EPS was an illusion (a $155M one-time tax-allowance release); strip it out and you own a ~9x-EBITDA late-cycle offshore play down 31% YTD on real but cyclical margin compression — WATCHING, not yet a buy, until 2H-2026 floater visibility confirms the ROV pricing thesis. | — | 8 |
| A boring enclosures-and-connectors company that bought and sold its way into the AI data-center build — now growing 50%+ with infrastructure orders up 100% organically; the re-rating to ~28x is largely earned, but the multiple now prices in the build continuing, and the legacy two-thirds of the business is still cyclical late-cycle industrials. | — | 1 |
| World's #1 potash producer + #1 ag-retailer, mid-cycle and cheap (~11x fwd P/E, 1.8x levered), self-help via portfolio simplification — a high-quality cyclical you buy near trough, not a compounder; BULLISH-tactical, not structural. | — | 0 |
| The tariff-fortified, lowest-cost EAF compounder is mid-upcycle with self-help volume still to land — but the +118% run already prices the recovery, so the edge is the multi-year normalized-earnings step-up, not the next print. | — | 1 |
| A retail-hedged Texas IPP that bought its way into the data-center super-cycle at 7.5x EBITDA and is buying back $1B/yr of its own stock — the AI-power thesis with the least crowded multiple and the most balance-sheet to prove; long while ERCOT scarcity holds and integration delivers, but the moat is gas + retail switching costs, not nuclear, and the bull case is now an integration-execution bet on a doubled, levered fleet under a brand-new CEO. | — | 8 |
| A fallen-angel GLP-1 franchise trading at a generic-pharma multiple on a still-growing branded book — but the de-rating is a verdict on durability (Lilly's tirzepatide is structurally better, semaglutide's US patent cliff is 2031–32), and the cheapness is only a buy if the oral-Wegovy ramp and the amycretin pipeline can defend share before exclusivity breaks. | — | 1 |
| A real, well-run precision-photonics/motion compounder priced like a 38%-EPS-growth story while actually compounding GAAP earnings backwards (~2% over 5yr) — the whole thesis rests on restructuring + AI-datacenter mix converting ~3% organic growth into margin expansion; WATCH/NEUTRAL near $151, not a buy at ~40x forward / ~30x EV/EBITDA until margins inflect. | — | 8 |
| A #2 process-control specialist compounding revenue at ~1.7x the market on a structural metrology-intensity tailwind and an AI-memory cycle — but priced at ~35-48x forward earnings with one customer at 23% and a third of sales in export-control-exposed China; own the business, respect the price. | — | 1 |
| A re-rated telecom-equipment turnaround wearing an AI-infrastructure mask — the optical/AI-RAN engine is real and accelerating, but the stock already prices the re-rating (P/E ~90, +109% in 12m) while ~92% of revenue is still slow-growth telecom/IP/patents. Right business, wrong entry. | — | 1 |
| A boring Indiana gas/electric utility that quietly became an AI-power landlord — a ~$28B 2026-30 capital plan, ~9GW of hyperscaler demand funnelled through a Blackstone-capitalised ring-fenced GenCo earning an unlevered IRR the 10-K says should BEAT its regulated return, and a 9-10% EPS CAGR the market is paying a deserved ~22-23x for. Own the contracted re-rate; the kill-switch is Amazon exercising its Mar-2029 option to halve the ADS contract. | — | 1 |
| The dominant solar-tracker franchise (>50% US, ~30% global, 11 straight years #1) with a clean, net-cash balance sheet and a beat-and-raise FY26 — but the FY27 guide already flags margin compression, and the whole bull case rests on developers safe-harboring around the OBBBA placed-in-service cliff (Dec 31 2027) plus a 45X manufacturing subsidy (~$380M, ~10% of revenue) that phases out 2030–2032. Quality is not in question; the multiple (~26x forward P/E, ~3x peer ARRY) and the policy clock are. | — | 1 |
| A regulated Florida-utility crown jewel (FPL) bolted to the world's largest renewables developer (NEER), trading at a 22x premium that prices the AI-power supercycle as a sure thing while the OBBBA tax-credit cliff and a $95B debt stack sit unpriced — own the moat, but the multiple already pays for the catalyst. | — | 1 |
| A platform-quality data moat (1,000× the field's reprogramming-screen data) wrapped around an unproven biology, priced at $3.1B pre-IND for a 2027 first-in-human — the bet is the engine, not the liver drug, and the engine won't be falsifiable for 24+ months while a rival is already in the clinic. | — | 8 |
| The category's brand and bandwidth leader, but the bet is binary on durable signal-at-scale and CMS reimbursement — not yet a tradeable security, and the moment a Synchron or Precision reaches a pivotal trial first, Neuralink's "lead" is narrative, not regulatory. | — | 1 |
| World's first commercial invasive BCI and the first BCI company to file a public listing — but it's a profitable-instinct EEG hardware vendor wearing a moonshot's valuation; the 4bn-yuan mark is paid for the NEO halo, not the Rmb108m EEG P&L, and NEO did zero revenue. WATCHING into the STAR Market print; the trade is the IPO mispricing, not the science. | — | 8 |
| The only BCI company that already ships a product people buy — but it is a $65M consumer-wearables licensing bet, not a brain-implant moonshot, and the entire thesis now rides on whether "Powered by Neurable AI" becomes Intel Inside or stays a $699 novelty. | — | 8 |
| Lead asset is dead (navacaprant 0-for-3 in Phase 3 MDD, program killed Jun 15 2026); NMRA is now a ~$280M-cap shell with ~$130M cash, two early CNS shots (NMRA-511 AD-agitation Ph2, NMRA-898 schizophrenia Ph1) and runway into Q3 2027 — a busted-binary option, not an operating thesis. WATCHING, not investable, until an NMRA-511 Phase 2b signal or a credible cash-floor/M&A backstop appears. | — | 8 |
| The structural thesis survives first contact with the filings, but the primary sources RE-PRICE the bear case both ways — the real SEC-disclosed backlog is $33.6B RPO (not the ~$47B web headline), the ClickHouse stake carries at $1.52B (not ~$4.2B), and the "profit" is a $780.6M non-cash mark sitting on a $128.0M operating loss — yet the same filings show genuine operating leverage (AI-cloud adj. EBITDA $174M / 45%), an unqualified FY2025 audit opinion, a removed going-concern doubt, and a financing toolkit (asset-backed against MSFT+Meta + $9.3B cash + prepayments) that is more real than the gap-crash bears allow. Still WATCHING / MEDIUM — the call is, and remains, funding execution, not demand. | — | 8 |
| A pre-revenue proteomics-tools optionality call dressed up as a "below cash" trade — at ~$2/share the net-cash floor is GONE (it re-rated to ~2x net cash) and you are now paying for a single-molecule platform that has placed exactly one customer (Baylor) and won't ship instruments until early 2027; bet on execution, not on the balance sheet. | — | 8 |
| A real subsea-autonomy technology wrapped in a broken micro-cap balance sheet — going concern, a near-empty backlog, Q1-2026 revenue collapsed to $160k, and a board-authorized path to a cumulative 1-for-250 reverse split and 1.5B authorized shares. The tech may survive; today's common stock is a melting ice cube. | — | 1 |
| A category-defining MRD franchise compounding ~35-40% with newly-positive FCF, but priced at ~13x sales for a still-GAAP-unprofitable company whose reported losses are masked only by $350M+/yr of stock dilution and a litigation rap-sheet (a $292.5M Guardant verdict on appeal) that the multiple ignores. | — | 1 |
| A Bitcoin treasury trading at ~0.33x mNAV with a name-brand promoter — the discount is the thesis and the trap; only a buyback-funded NAV-accretion flywheel or a takeunder closes it, and the Dec-2026 Kraken maturity is the clock. | — | 8 |
| A melting-ice-cube hereditary-cancer franchise priced at 0.7x sales because the market doubts the MRD pivot lands before the cash and the revenue covenant run out — cheap for a reason, not yet cheap enough to be safe; WATCHING for a clean MRD coverage + reacceleration signal. | — | 8 |
| A 13%-gross-margin electrical contractor priced at 43x forward EPS on a flawless-execution datacenter/grid narrative — great business, dangerous price; the same clean-energy fixed-price risk that halved Primoris and gutted MYRG itself in 2024 is not in the multiple. WATCHING for a pullback. | — | 8 |
| A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patient acquisition to lower-cost recurring referrals — but it must prove the operating-leverage turn at ~$45M revenue before the Avenue debt covenants and a sub-$1.50 stock force another dilutive raise; bullish on the model, watching the proof. | — | 1 |
| A subsidized option on Western rare-earth independence — the DoD's $110/kg NdPr floor turned a money-losing concentrate miner into a vertically-integrated magnet company with capped downside, but the equity already prices the 2028+ 10X build at ~134x forward earnings, so you're paying full freight for a thesis that depends on execution and elevated NdPr prices. | — | 1 |
| A blueberry-sized, battery-free epidural stimulator with a Medtronic-grade team and a clean FDA IDE — but it is a single-asset, sub-$30M minnow in a field of nine-figure whales, and its closest peer (Inner Cosmos) already has the clinical lead. | — | 1 |
| A genuinely elite fabless analog compounder (43% 5yr ROIC) that has become a high-beta levered call on Nvidia's power-delivery socket — priced at ~112x trailing / ~49x NTM EV-EBITDA (peer median ~21x) while carrying an unremediated material weakness, an adverse ICFR opinion, and a live securities class action. Own the franchise, not this multiple; the gap between the Vera Rubin "70% share" dream and the Blackwell "allocation-at-risk" reality is the whole trade. | — | 1 |
| A dead company — Zimeno/Monarch shipped 500 real tractors but never a real business; collapsed into an assignment-for-creditors and an IP-only Caterpillar acqui-hire. Uninvestable; value here is the post-mortem, not a position. | — | 1 |
| A sub-scale, fraud-born SPAC orphan now run by a credible defense fixer — Vigoride 7 finally flying real payloads buys a narrative, but ~$10M of revenue against a perpetual equity-dilution engine and a $438.6M accumulated deficit makes the equity a momentum lottery ticket, not an investment. BEARISH structurally; the float is a squeeze toy, not a moat. | — | 8 |
| A 109-year-old radiator maker that 80/20'd itself into a data-center liquid-cooling growth story and got re-rated 14.7x in five years — the asset is real and a single hyperscaler has pre-committed >$4B of cooling for CY27–29, but at ~38x forward / ~133x trailing the price already pays for flawless execution while Q4 just showed the margin and supply-chain cracks that flawless execution doesn't have. Own the post-RMT pure-play on a data-center capex scare or a second margin miss — not here. | — | 0 |
| A real mRNA platform priced like an oncology winner before the oncology has won — the +94% YTD melt-up has run past a still-burning, policy-exposed vaccine business with a $1.3B IP tail. | — | 1 |
| A toll-booth on every wafer fab (>85% of WFE process steps) wrapped in $4B of Atotech leverage — the AI-WFE cycle is paying down the debt fast, but at ~39x forward non-GAAP EPS and ~2x the median target, the cycle is already in the price. WATCHING, not buying, until a WFE wobble resets the multiple. | — | 8 |
| Europe's only credible frontier lab — a sovereignty-and-infrastructure bet, not a model-quality bet; the moat is regulatory/political, the risk is that "good enough, in Europe, on-prem" gets out-priced by Chinese open weights before the €20B mark is earned. | — | 1 |
| A roll-up dismantling itself — the sum-of-parts breakup (Residential sold, Food Processing spun July 6) plus a real Commercial Foodservice demand inflection is the value-unlock; but you are buying it at the 52-week high days before the spin removes the cheapness that was the thesis, into tariff-squeezed margins and a $1.77B 2028 debt wall. | — | 8 |
| A sub-scale MEMS-lidar perennial bleeding ~$60M/yr against ~$1M of revenue, now a distressed-asset roll-up (bought bankrupt Luminar + Scantinel) funded by a toxic convertible + sub-$1 ATM; the tech is real but the cap structure and going-concern math make equity a financing-driven option, not an investment — BEARISH, avoid. | — | 8 |
| A real operating turnaround (FY25 first positive operating income, +$76M operating cash) trapped inside a busted-SPAC capital structure, a going-concern flag, and a -48% Q1 air-pocket — cheap at ~0.3x sales but the convertible loan and demand lumpiness make it a high-variance WATCHING, not a buy until the next two quarters prove FY25 wasn't the peak. | — | 8 |
| The cleanest AI-infrastructure compounder on the board, now de-rated to ~20x forward on a real fear — Azure deceleration meeting a $190B/yr capex wall — that is more a timing question than a thesis-breaker; the moat (RPO $633B, M365 distribution, ~27% of OpenAI) is intact, the FCF is the variable to watch. | — | 1 |
| A real, founder-led cyclical recovery already 56% priced in — the tape (Q4 +35% YoY, 30.6% non-GAAP op margin, "largest booking month in 4 years") confirms the turn, but at ~37x forward run-rate earnings and a dividend that ate 113% of trough FCF, you are paying peak analog multiples for an early-cycle balance sheet still carrying $5.5B debt and a deferred Malaysian tax bomb. Quality compounder, wrong entry. | — | 8 |
| Metsera is no longer an investable equity — Pfizer closed the buyout at $65.60 cash on 13-Nov-2025; the only live instrument is the non-transferable CVR (up to $20.65/sh on three obesity-approval milestones), realistically worth a fraction of par, and the durable trade is the read-through to PFE/NVO/LLY and the amylin thesis, not MTSR. | — | 1 |
| The cheapest mega-cap in the AI complex (~18–20x fwd P/E) compounding ad revenue +33% — but it has converted itself into a single-variable bet on whether $125–145B/yr of AI capex earns its return, and the market won't re-rate until the depreciation wave proves out. | — | 1 |
| The best-funded, worst-priced AI franchise in megacap — a $200B+ ad engine bankrolling a $135B/yr superintelligence bet the market is refusing to underwrite; the stock pays you to wait while the ad-AI flywheel already prints, but the open-weight thesis is dead and the capex ROI clock is now running loud. | — | 1 |
| A $850M valuation at inception for a read-only ultrasound BCI whose recording modality still needs a hole in the skull — Merge is a bet on Altman, OpenAI distribution, and a 3-to-5-year science miracle (through-skull fUS + sonogenetic gene delivery), not on a product; nothing to underwrite until it shows transcranial human signal that Forest Neurotech itself has not yet shown. | — | 8 |
M MeiraGTxcatalyst in 43d | A de-risked gene-therapy platform hiding inside a $0.85B shell — bota-vec reacquisition + Lilly/Hologen non-dilutive funding gives MeiraGTx three near-term shots (xerostomia BTD, XLRP filing, riboswitch-GLP1 optionality) the market is pricing as one coin-flip; the bet is on execution-to-launch, not science. | — | 1 |
| Cheapest large-cap medtech (fwd P/E ~13x, ~half of BSX/SYK) finally inflecting — PFA + Hugo + an Elliott-forced cost/portfolio reset put a credible re-rating in play, but the whole thesis rests on one unproven number: does organic growth hold above 5%? | — | 1 |
| A genetics-platform biotech whose lead asset just printed real proof-of-concept in a disease with zero approved drugs — and the stock fell 35% because Vertex's inaxaplin is two years ahead. The bet is whether oral once-daily APOL1 inhibition is a two-horse race or a winner-take-most one. | — | 0 |
| A real AI-optical DSP ramp (Keystone/Rushmore) bolted onto a flat legacy-broadband body and an unreserved $160M+ arbitration — the stock at $89 already prices the pure-play outcome the income statement hasn't earned; the 80% post-Q1 spike has run past sell-side fair value ($68). | — | 1 |
| "The 'Maxar' instrument has dissolved — Lanteris (the satellite-builder) was sold to Intuitive Machines (LUNR) in Jan 2026, leaving the private residual = Vantor, an Advent carve-out repricing 30 cm imagery as defense-software ahead of a ~$14.5B exit. WATCHING the Vantor IPO/strategic-exit; the only tradeable Maxar today is LUNR's space-systems half." | — | 1 |
| An irreplaceable U.S. beryllium monopoly wrapped in a low-margin pass-through metals business and now priced like a secular-growth compounder (~34x fwd vs 18-20x historical, above every Street target) — the asset is real, the multiple is the bet. | — | 1 |
| A toll road on global consumption priced like a bond proxy — the moat is intact and value-added services are compounding at 2x the network, but the stock has de-rated to ~24x forward because the market is (rightly) pricing two live structural threats — stablecoin disintermediation and large-issuer network defection (Capital One/Discover) — that bulls keep waving away. WATCHING, lean BULLISH on weakness. | — | 0 |
| The purest non-utility way to own the AI-electricity buildout — a #2 infrastructure E&C contractor whose record $20.3B backlog and 34% Q1 growth are real, but the stock already prices ~40x forward EPS, so the bet is on the cycle's *duration*, not its existence. | — | 0 |
| Best-positioned #2 in the custom-AI-silicon duopoly with an NVIDIA-blessed optical moat — but at ~$310 / ~109x trailing non-GAAP EPS the stock has priced in flawless execution AND already round-tripped a 2025 Trainium-loss scare; own the business, fade the entry, wait for a hyperscaler-wobble re-rate. | — | 1 |
| MARA is a $5.7B-cap, 380M-share leveraged Bitcoin beta machine quietly trying to morph into an energy/AI-HPC landlord before its mining margins and its 2027 convert puts catch up with it — the AI pivot (Starwood JV, Exaion, the $1.5B Long Ridge gas plant) is the only thing that could break the "two-thirds-of-net-liability-is-just-a-BTC-ETF-you-pay-fees-on" trap, and it is 100% unproven (zero material AI revenue). At ~9x EV/sales with a -$1.0B Adjusted-EBITDA quarter just printed, you are paying a premium-to-spot-BTC for execution risk; bullish only if you are really just bullish BTC and want operating + dilution leverage on top. | — | 8 |
| A quietly excellent RF-and-photonics compounder that the market has finally noticed — fab-lite 56% gross margins, three secular legs (defense, AI data-center optics, telecom), a net-cash balance sheet after killing its 2026 converts, but now priced at ~54× forward with an AI-optical multiple it must keep compounding into; great business, demanding entry. | — | 0 |
| The arms-dealer of the AI optics build-out — Lumentum owns ~50-60% of the 200G/lane EML laser chip that every 1.6T transceiver needs, NVIDIA just bought $2B of preferred to lock its capacity, and revenue is compounding ~90% YoY off a real telecom trough; but at ~52x forward earnings with two customers = ~40% of revenue and a $3.8B convertible stack now in-the-money, the price already discounts flawless execution. | — | 1 |
| The first company poised to win an FDA label for "lifespan extension" in any species — a genuinely novel regulatory beachhead on a large, growing owner-pays pet-pharma market — but the bet rides on one not-yet-read-out 1,300-dog trial, a surrogate-style ("reasonable expectation") approval, and a single CMC section still outstanding; WATCHING (privately ownable conviction, no tradeable instrument) with the STAY lifespan readout as the binary. | — | 0 |
| The best-run business in industrial gases and a near-perfect compounder — but at ~29x forward EPS on a flat-volume, ~mid-single-digit-organic engine, you are paid in quality and capital return, not in upside; the market already knows it is great. | — | 8 |
L Lightwave Logiccatalyst in 43d | A 35-year science project that just turned the corner from lab to foundry PDK — credible polymer-photonics platform now inside Tower & GlobalFoundries flows, but $237K of revenue against a $1.5B cap means you are buying a 2027-28 design-win option, financed by perpetual dilution, with a 17.7% short base betting it stays a promise. | — | 1 |
| The purest public-markets-bound bet on AI's copper wall — but it is racing NVIDIA, Broadcom and TSMC to commercial CPO from outside the package, and "2027 volume shipments" means the $4.4B mark is paid entirely on a roadmap. | — | 1 |
| World's first listed pure-play photonic-computing stock — and a ~640x-sales SOE-backed China name with $15M revenue, a $185M annual loss and Huawei owning 98% of its market; the technology is real, the equity is a momentum trade priced for a future that is 5 years out. | — | 1 |
| The first company to put epigenetic age-reversal into a human body — a binary, single-asset bet where a clean Phase 1 safety read on OSK reprogramming is worth more than the whole longevity field's $4B+ of pre-clinical promises, and a single inflammation or tumor signal ends it. | — | 1 |
| A great battery operator strapped to a collapsing demand curve and a U.S. subsidy that is its only profit — the franchise is real, but the 2027-2032 order book just lost ~$9B of contracted Ford/FBPS volume and AMPC repeal is an existential tail risk; WATCHING, not buying, until the ESS pivot proves it can replace lost auto cells at a real margin. | — | 1 |
| A genuine low-power-FPGA franchise riding a real AI-server attach cycle off a cyclical trough — but the tape already prices flawless multi-year execution (~20x a $1B run-rate that doesn't exist yet, ~76x fwd non-GAAP EPS), and the $1.65B AMI deal converts a pristine net-cash balance sheet into ~$950M of fresh debt right at the top. Great business, dangerous entry price. WATCHING, not chasing. | — | 8 |
L LanzaTechcatalyst in 45d | A real carbon-recycling technology trapped inside a going-concern microcap — the science works, the business model to monetize it does not yet, and the equity is a binary on insiders (Khosla/Brookfield) funding a cohort-licensing pivot to cash-flow breakeven before dilution and Nasdaq erode it to zero. WATCHING with a bearish tilt. | — | 1 |
| Best-in-class etch monopoly riding a once-a-decade memory/AI WFE upcycle into record margins — but at ~69x guided FY26 GAAP EPS the tape, not the business, is the risk; the moat is real, the multiple is borrowed from the future. | — | 1 |
| A counter-cyclical compounder mid-re-rate — the destocking trough is behind it and the FY26 earnings snapback is real, but at ~¥2,900 / +81% off the lows the easy money is made; tariffs and a structurally weak NA ag market cap the upside from here. | — | 1 |
| A genuinely profitable, self-funded in-vivo gene-therapy platform whose entire growth narrative now rests on ex-US VYJUVEK launches (US is flat) plus an unhedged binary KB707/NSCLC option — priced at ~23x sales as if both already work. | — | 1 |
| A real driverless-trucking deployment (Atlas, 28 trucks, 23.5k paid driverless hours) wrapped in a broken SPAC balance sheet — single-customer revenue of $3.8M, a going-concern flag that a $100M PIPE only pushes to Q2'27, and ~$150M/yr burn; it is an option on the 2H'26 long-haul launch, not yet a business, and Aurora is the same option at 10x the scale. | — | 8 |
| The toll-booth on chip yield — a ~58%-share process-control near-monopoly whose revenue scales with chip *complexity*, not wafer volume, so it compounds even through capex air-pockets; the only real debate is the price you pay, not the quality of the business. | — | 1 |
| Best-positioned AI-infrastructure "picks-and-shovels" test name with a real moat and a re-accelerating order book — but priced for perfection at ~54x trailing / ~32x forward after a +100% year, with reported numbers flattered by a one-time IEEPA tariff refund and Spirent inorganic lift. Quality compounder, wrong entry; WATCH for a cyclical/multiple reset. | — | 8 |
| A genuinely good optical-imaging instrument company wearing three failed business models — capital-starved ($158M total, no priced round since Dec-2023) and IPO-irrelevant while the rest of BCI raises billions; WATCHING, not investable, until a real revenue line or a strategic acquirer appears. | — | 8 |
| A spec-locked, sole-source space-and-defense subsystem roll-up riding Golden Dome and OBBBA tailwinds at ~50% growth — but it is a leveraged (2.1x D/E) PE-sponsor exit story with a live material weakness, ~$680M of floating-rate debt, and a still-rich ~34x forward EV/Adj-EBITDA; the 58% drawdown is a Trive-Capital supply unwind, not a thesis break. WATCHING (coverage note: this is fundamentally a defense prime-supplier — see exclusion flag). | — | 1 |
| The record 2026 print is mostly a Section-232 tariff-premium + metal-price-lag windfall on flat real volume — a high-quality fabricator priced for perfection at a 52-week high after a 2.5x run, with consensus already pointing down. | — | 1 |
| A reserve-distorted GAAP optic hides a clean ~6-7% operational compounder that has visibly grown THROUGH the STELARA cliff; at ~20.6x forward adj EPS it is a quality-at-fair-price hold whose re-rate gate is talc tail-risk resolution and Orthopaedics/Ottava optionality, not the P&L. | — | 8 |
| A funded, certification-stage option on being the first FAA-certified eVTOL — real moat in vertical integration + a fortress balance sheet, but priced for flawless execution with zero core revenue and a binary 2026 catalyst. | — | 1 |
| A newly-merged global #1 in food-processing automation, ~17% off its March high, mid-cycle on a real integration story — the bull case is synergy-and-deleveraging math the market half-believes; the bear case is two unremediated Marel control weaknesses and a $5.4B goodwill/intangible stack sitting on a still-cyclical protein-capex book. | — | 1 |
| "A picks-and-shovels AI-infrastructure compounder hiding inside an EMS multiple — the bet is that liquid-cooling/power vertical integration + relentless buyback keep core EPS compounding 20%+, but at ~29x forward core EPS the re-rate is mostly done and a single 16% hyperscaler customer + AI-capex cyclicality are the trapdoors." | — | 8 |
| A single-asset US copper developer (Santa Cruz) levered to a structural copper deficit and the "domestic critical-minerals" trade, wrapped in a Friedland promote and a still-unfunded $1.24B build — own the deposit and the EXIM optionality, but underwrite the dilution, not the PFS NPV. | — | 1 |
| The best AI-drug-design platform on earth, owned by Alphabet and priced like a winner — but it has not yet validated a single molecule in a human, and a Phase-1 start ("a drug entered a person") is not proof the drug works; bullish on the science, watching for the first readout that AI changed the base rate, not just the timeline. | — | 8 |
| A 74-year-old records-storage cash cow funding a debt-financed hyperscale data-center pivot — the AI re-rating is real but it sits on a credible Gotham short (AFFO > FFO, ~5x vs alleged ~9x leverage, an SEC Adj-EBITDA comment-letter trail, negative book equity), so the bet is whether the cash flows are as clean as the headline AFFO says. | — | 8 |
| A debt-levered, cash-machine LEO monopoly being re-rated on spectrum scarcity — own the durable EMSS/IoT/Aireon annuity, but the spectrum-takeout dream is now mostly in the price. | — | 1 |
I | A Bitcoin miner that won the AI-infrastructure lottery — NVIDIA both rents IREN's GPUs and bought its equity at $70, validating the liquid-cooling pivot Culper shorted; the bet is now execution and dilution, not survival. | — | 1 |
| A near-death epiwafer monopolist just got bought out of bankruptcy by its own customer — own the InP photonics call, not the company; the AI-optical TAM is real but the float is a recovery option on a chronically capex-starved, margin-thin foundry whose two largest customers now sit on its board. | — | 1 |
| A real RNA-medicine platform finally turning into a P&L — but the stock is a pelacarsen option with seven launches as the floor. Own the platform, size for the binary. | — | 0 |
| A re-rating active manager hiding inside a melting active-mutual-fund book — the QQQ fee-switch and ETF/Asia flywheel are real and underpriced, but the same OppenheimerFunds intangibles it just wrote down $1.8B are the structural rot; quality-of-earnings and the MassMutual overhang cap the multiple. Net BULLISH-but-cheap-for-a-reason: a high-teens total-return name, not a compounder. | — | 8 |
| The best razor-and-blade in medtech, finally facing real razors — an 84%-recurring soft-tissue surgical monopoly compounding mid-teens, but priced at ~37x forward EPS just as Medtronic and J&J arrive and US procedure growth decelerates 19%→14-16%. Quality is not the question; the entry price is. | — | 1 |
| A de-SPAC moonshot that just bought its way into a real revenue base — Lanteris (ex-Maxar) makes LUNR a ~$900M-revenue satellite prime, but the legacy lunar business still loses money on every fixed-price mission, 78% of legacy revenue is one customer (NASA) facing a 23% budget-cut proposal, and the stock prices a flawless transition the company's 0-for-2 landing record hasn't earned. WATCHING, not yet a position — needs IM-3 to land upright and Lanteris margins to prove out. | — | 8 |
| A de-risked HAE asset (lonvo-z, 87% attack cut, BLA filing) wrapped in a financing-and-competition problem — the cure is real, the question is whether anyone buys a one-shot in a market with 11 approved drugs, and whether a $1.9B-cap, 38%-shorted clinical-stage burner reaches launch without another dilutive raise. | — | 1 |
| A barely-profitable IDM whose equity 10x'd on a recapitalization-and-validation narrative (US gov, Nvidia, SoftBank, hyperscaler 18A interest) while Foundry still bled $10.3B in FY25 — the story is priced as if the turnaround already happened. WATCHING, with a bearish lean on valuation. | — | 1 |
| Best-in-class techbio platform with the right founder and tier-1 pharma validation, but it is a pre-clinical, cash-burning private whose entire value rests on AI-discovery delivering in the clinic — the one thing the whole sector has repeatedly failed to do. WATCHING, not a position; the be-early payoff is a 2027-28 IPO window, gated on a first IND and a non-down round. | — | 8 |
| First clinically-validated AI-drug-discovery platform with a real biopharma cash engine, but the stock prices a Phase III win that the +98mL Phase 2a does not yet earn — long the platform, fade the IPF hopium. | — | 8 |
I Innoviz Technologiescatalyst in 42d | A real Tier-1 LiDAR product with marquee OEM design wins, trading like an option that expires — the bet is whether VW/Mobileye SOP volume arrives before the Sept-2026 Nasdaq clock and the cash runway force a dilutive reverse split. | — | 1 |
| The cautionary tale of the agtech bubble — a $3.5B "biology-will-rewire-farming" thesis that survived only by shrinking into a soil-carbon broker; the equity is impaired by ~94% and the surviving business is a thin-margin MRV middleman in a market with an additionality problem. WATCHING, not buyable — and not investable until there is a real revenue/margin disclosure, not a credit-tonnage press release. | — | 1 |
| A $7.4B-backlog ADAS design-win story strapped to a perpetual-loss P&L — flat revenue, ~30%-of-sales dilution, $230M net debt; the Wuxi sale + 2026 core ramp is the only bridge to credibility, and it's not yet built. | — | 8 |
| The best-positioned European BCI pure-play and the only graphene-native one — but it is a Series-B, pre-revenue spin-off two full funding rounds behind Neuralink/Precision, and its material moat is unproven precisely where its closest competitor (Precision's Layer 7) already has FDA clearance; a watch-and-wait private, not yet investable, gated on a Series C + a graphene-specific regulatory de-risking event. | — | 8 |
| A George Church / Flagship gene-editing platform whose entire "freedom-to-operate" moat — edit a rival's already-GM trait and call it your own — is precisely what Corteva is suing to invalidate; a Jan-2026 ~33% site layoff one year after a "robust" $144M raise says the commercialization clock is running faster than the cash. | — | 1 |
| A real operational turnaround is underway (rev re-accelerating, margins expanding, share count shrinking), but the stock has already sprinted past consensus into a Roche-Axelios competitive collision and a 40%-NIH-cut research recession — the easy money in the recovery is made. | — | 1 |
| A debt-free, founder-controlled electrical/mechanical contractor compounding EPS ~50%/yr on the data-center build-out — a genuinely great business, but the tape has run to ~38x trailing on TTM EPS ~$19 and ~13.8B mkt cap, pricing in continued hyperscaler capex and flawless M&A integration with a residential anchor already dragging; WATCHING, not chasing, into the next print. | — | 8 |
| A real, well-run subsystem turnaround riding a genuine WFE upcycle — but at $98 (7x off the lows, EV/EBITDA ~23x, ~32x forward EPS) the stock has front-run the margin story it hasn't yet delivered; the sell-side target ($81.71) now sits BELOW the price and insiders are selling. WATCHING, not chasing — the edge is on a pullback to ~$60s or a Q2 margin miss, not here. | — | 8 |
| Best-validated of the AI-bio private cohort — Takeda/Bayer/Lilly de-risk the platform's *business model* and IAM1363 is a real clinical asset, but the lead program walks into the most crowded oncology target on earth and the AI-discovery class has a 100% record of disappointing in the clinic; WATCHING for IAM1363 dose-optimization efficacy + a disclosed valuation before any conviction. | — | 8 |
| The best modulator in AI optics — but a modulator-only company in a market where the indium-phosphide laser, not the modulator, is the scarce asset; the $80M Series C buys it a foundry-scale shot at owning the TFLN layer before silicon-photonics incumbents fold thin-film into their vertically integrated stacks. | — | 1 |
H Hyperfinecatalyst in 42d | A real, FDA-cleared portable-MRI razor finally finding its blade — Q1 device units +67% and runway into 2028 de-risk the going-concern story, but at ~$22M revenue and a ~$140M cap it is still a sub-scale, founder-controlled call option on point-of-care neuro-imaging, not yet a business. | — | 1 |
| A bitcoin miner that quietly turned into a hyperscaler landlord — ~$16.8B of base AA-/Google-credit lease backlog now dwarfs the BTC story, but the equity still trades and bleeds on bitcoin, and the Trump-adjacent ABTC sub is the governance hair. | — | 1 |
| Best-in-class low-cost copper-gold operator that just deleveraged to ~zero net debt and bought a US-copper growth pipeline (Copper World + Cactus) at the top of a speculative copper rally — high operational conviction, but the multiple already prices the growth and the cycle, so it is a quality name to own on a copper pullback, not at a record-high tape. | — | 8 |
| A breakup that has already done its job on the multiple — automation re-rates fairly post-spin, aerospace (HONA) is the cleaner long, but at ~21x blended and with the catalyst (June 29) priced, the easy money is made; own HONA, hold/trim HON. | — | 8 |
| A 25 EH/s green Bitcoin miner that liquidated its entire treasury to fund a credible-but-unfunded pivot to AI compute — the stock now trades on a CAD $3.5B Gigafactory dream that $23M of cash cannot pay for. | — | 1 |
| A re-rated AI-infra catch-up trade where the *quality* of the story (high-margin Networking) is real but the *price* now bakes in flawless Juniper integration and a server-margin recovery that hasn't been proven — own the franchise, not the multiple. WATCHING, not chasing at ~13x. | — | 8 |
H Hesai Groupcatalyst in 43d | The clear global LiDAR volume leader, now GAAP-profitable and pivoting into physical-AI sensing — but the entire equity is hostage to a single binary it cannot control: the U.S. appeals-court ruling on its DoD "Chinese Military Company" designation, with a hard June 30 2026 contract-ban trigger. | — | 1 |
| Best-in-class aerospace-aftermarket compounder firing on all engines (18% organic, record margins) — but the moat is in the price; at ~60x forward earnings the stock is a great company priced as a bond you can never lose on, and any organic deceleration re-rates it hard. | — | 1 |
| A tailwind expressed through the wrong vehicle — Hastings owns no control of its flagship (passive 40% under Wyloo), ~A$5M cash and <12mo runway, and is betting survival on a 49% stake in an unproven, Chair-linked Thai processing plant fed by third-party African monazite. Right commodity, wrong company. BEARISH structurally; binary upside only on the Q4-2026 Thai cash-flow proof. | — | 8 |
| A profitable liquid-biopsy oncology franchise quietly cross-subsidising a binary, USPSTF-gated bet on blood-based cancer screening — the re-rating from $52 to $130 already paid for the Shield optionality, so from here you are paying ~11x sales to be long a single 2026 guideline decision. | — | 0 |
| The profitable, un-hyped grandfather of non-invasive BCI — a 27-year Austrian bootstrap that quietly owns the research-EEG install base and is turning recoveriX neurorehab into a franchise annuity; a real cash-flowing business but NOT a tradeable IPO candidate (no venture capital, ~$24M est. value, founder-owned), so it is a WATCH-the-category tell, not a position. | — | 8 |
G | The crown jewels and the brain already left for Nvidia for ~$17–20B; what remains is a cash-rich but architecturally-cornered inference cloud whose flagship Saudi demand evaporated — a melting-ice-cube neocloud, not the LPU disruptor the headlines sold. | — | 1 |
| A levered, structurally-loss-making graphite-electrode pure-play whose old take-or-pay earnings are gone, now priced as a distressed call option on a 2026 electrode-price recovery that has to clear a 2029 debt wall — own the bonds' problem, not the equity, until pricing turns or the balance sheet is fixed. | — | 1 |
| The cheapest mega-cap AI franchise — DeepMind's full-stack (TPU → Gemini → 15 products) just proved monetization (Cloud +63%, $462B backlog, AI Overviews monetizing at parity), so the AGI optionality is a free call; the real bet is whether the Dec-2025 Search remedy survives appeal and capex discipline holds. | — | 1 |
| A spine-implant roll-up wearing a robotics badge — the robot is <5% of revenue and a razor-and-blade pull-through, not the story; the real bet is whether mid-single-digit organic growth re-accelerates as NuVasive integration scars heal, at a justified ~16x value-medtech multiple. | — | 0 |
| GSAT is no longer a fundamental story — it is an Amazon merger-arb at $90/sh (≈10.8% gross spread, 2027 close); buy the deal-break protection (Apple re-signed, $592M reverse break fee, FCC defends the spectrum, vote already done), not the satellites. The only real risk is regulatory drag, not deal failure. | — | 1 |
| A copper-and-cobalt growth story wearing a coal-and-trading costume — re-rates only if Nagle delivers the volume ramp (1Mt Cu by 2028) and keeps buying back stock; the integrated marketing book is the real, under-priced moat, but a 2027 SFO trial and a thin balance-sheet cushion cap conviction at MEDIUM. | — | 8 |
| A de-risked cash shell ($373M, no debt, ~$207M EV) wrapped around a still-shrinking lab-automation pivot — the balance sheet is the asset, the income statement is the warning; long the optionality only below cash, not the story. | — | 0 |
| A balance-sheet roll-up of the fragmenting Western defense-satcoms supply chain (DataPath→Stellar Blu→Comtech) wrapped around an orbit-agnostic ground-terminal franchise that wins whether GEO or LEO wins — but the stock already prices the re-rating (~23x EV/EBITDA) while organic margins are still convalescing and two customers are 44% of revenue. | — | 1 |
| The best-positioned Western power-equipment franchise of the AI-power cycle — a real gas-turbine oligopoly with a $150B+ backlog and SRA-secured pricing — but at ~52-60x forward earnings the market has already priced near-flawless margin execution to 2028, while GAAP earnings are flattered by ~$7B of one-time gains (tax-allowance release + Prolec remeasurement) that mask a still-modest ~8% operating-EBITDA base. Quality is high; the entry is not. | — | 8 |
G | The single-partner-concentration bear point is dead — Gero now has TWO pharma validations, and the bigger one (Chugai/Roche, exclusive worldwide antibody rights, up to ~$250M milestones + royalties) is disclosed on a listed Roche subsidiary's own corporate filing, the most credible source in this dossier. Plus an open-sourced sequence-to-molecule model (ProtoBind-Diff). Still WATCHING (private, no public security, no named owned IND asset), but the watch is materially higher-quality — conviction on the platform-validation leg rises from "one partner, unfalsifiable" to "two top-tier pharma partners + a verifiable open-source artifact." The asymmetric event is now a partner advancing a target to the clinic or an institutional/crossover up-round. | — | 1 |
| The best-capitalized pure-play AI chemistry shop with the strongest pharma-validation signal in the category — three blue-chip deals (Lilly, Gilead, Incyte) and a $120M Incyte expansion say partners believe GEMS designs hard targets others can't; but it is still 100% preclinical with no IND on record, so the entire thesis hinges on the first wholly-owned clinical readout converting "partners pay us" into "our molecules work in humans." Watch for the first Genesis IND and any disclosure of a clinical candidate's identity. | — | 8 |
| A genuine "platform proves out in the clinic" bet whose ENTIRE near-term value rests on one drug (GB-0895) winning a crowded long-acting-TSLP race — own the AI-bio category leader only on a pullback, because at ~$2.2B with a 2028 cash wall and an August lock-up, you are paying platform multiples for what is currently single-asset, single-readout binary risk. | — | 8 |
| A sub-1%-share, structurally subscale crypto exchange whose core trading revenue is already flat — kept alive by recurring related-party rescue financing from its own founders; the ~85% post-IPO drawdown is the market correctly re-rating a $3.3B IPO to a ~$0.5B going concern, and nothing in the numbers says the floor is in. | — | 1 |
| A debt-free, 59%-gross-margin device compounder mispriced as "space" — the real bet is whether the FY25–26 fitness-wearable share surge is a durable re-rating or a post-pandemic echo that decays back to mid-single-digit growth at a 24x multiple that already pays for the good case. | — | 0 |
| The world's lowest-cost path to vertically-integrated lithium is finally arriving (50%+ self-sufficiency, 60Mt LCE resource) just as the price cycle turns — but the equity has already front-run the turn (P/E ~39x, H-shares ~11% above consensus), so this is a high-beta call on lithium >RMB120k/t and Beijing keeping Jianxiawo offline, not a value entry. | — | 8 |
| Two companies stapled together — a volatile crypto merchant bank wrapped around an emerging West-Texas AI-datacenter annuity (CoreWeave, >$1B/yr × 15yr); the stock has decoupled from bitcoin and now trades the Helios optionality, but CoreWeave single-tenant concentration plus a marked-to-market house book make conviction event-dependent, not durable. | — | 1 |
| A debt-free diagnostics lab trading at ~cash with a real, free oncology call option (FID-007) — but you are paid to wait through a 2026 revenue air-pocket and an unquantified HRSA/DOJ False-Claims tail larger than the market cap. | — | 8 |
| A 28-year-unprofitable, perpetually-dilutive fuel-cell manufacturer re-rated 135% YTD on an AI-data-center pipeline that is still non-binding LOIs — the story is real, the order book is not, and the funding model is the share count. | — | 1 |
| A world-class copper-and-gold orebody wrapped in a structurally leaky holding company — you buy FCX for the copper supercycle and the Grasberg restart, but ~half of every Indonesian dollar exits to the Indonesian state before it reaches your share, and Grasberg execution (not the copper price) is what actually decides the stock through 2027. | — | 1 |
| A melting traditional active-manager (structural fee/flow decay, only WAM resolved) wearing a tokenization halo too small to matter yet — the BENJI option is real but ~0.15% of AUM; you are buying a 4% yield and a turnaround in active fixed income, not a crypto stock. | — | 8 |
| Best-in-class capex-light gold-royalty compounder whose Cobre-Panamá hole is now refilling at zero cost in the guide — but the stock already de-rated ~23% off its Feb high while gold hit records, so the premium is the position; long the model, patient on the entry. | — | 8 |
| The only Western pure-play on AI test-intensity, with a real Smart Matrix/HBM4 earnings inflection — but priced at ~57x forward EPS for ~18% growth on a 7-9% GAAP-margin cyclical, with SK hynix + NVIDIA now ~40% of revenue and Technoprobe taking foundry share. Great business, demanding multiple. WATCHING for a cycle wobble. | — | 8 |
| The cheapest electron-storage on the grid at the worst round-trip efficiency on the grid — a genuine multi-day monopoly whose moat (iron at $0.10/kWh, a US steel-mill factory, ArcelorMittal upstream) is only worth owning if regulators keep paying for firm capacity rather than cheap throughput; the Google $1B deal proves demand exists, the sub-40% RTE proves the bet is on policy and capacity value, not arbitrage. | — | 1 |
| Forest is a nonprofit research instrument, NOT an equity — the tradeable BCI bet it incubated walked out the door as Merge Labs (Altman/OpenAI, $850M); track Forest as the science-de-risking front-end, position via Merge or Butterfly (BFLY), never Forest itself. | — | 8 |
| A levered call option on US grid-storage demand and IRA/OBBBA domestic-content rules — record $5.6B backlog and two hyperscaler deals validate the funnel, but 7–13% gross margins, a 50%-H2-weighted year, and a stock above the average analyst target leave it priced for flawless execution it has repeatedly failed to deliver. | — | 1 |
| The best-run solar manufacturer on earth, but ~$1.6B of FY25's $1.5B net income is a US tax credit — you are not buying a module company, you are buying a leveraged, policy-dated bet that the 45X subsidy and the domestic-content wall hold through 2032. | — | 1 |
| A two-asset Zambian copper miner wearing a three-asset valuation — long the Panama re-rate and the copper deficit, but the price already underwrites a restart that is a political grant, not a corporate decision; own it for the option, size it for the binary. | — | 8 |
| A post-scandal regulated T&D pure-play repricing from "governance-risk discount" to "data-center transmission growth" — owns the right wires (24,000 mi, PJM, +45% peak load) and a credible outsider CEO, but the thesis is a 6–8% EPS-CAGR rate-base compounder, not a multibagger; Householder-related securities litigation (loss "probable", unestimable) and Baa3 balance-sheet tightness are the live tail risks. | — | 8 |
| A real lunar/launch franchise wrapped in a serial-failure rocket, a money-furnace P&L, and a ~32x-sales price — the Golden Dome/SciTec defense pivot is the only thing that justifies the multiple, and Eclipse first-flight is the binary that settles it. | — | 1 |
| The best-run business in tokenized credit — a real, ~50%-EBITDA-margin lending-tech engine wearing a crypto multiple — but it is one HELOC product, one founder's super-vote, fresh material weaknesses and a million-record breach away from re-rating the wrong way; great company, priced like a story, own it cheaper. | — | 1 |
| The category's pace-setter and best-funded vertically-integrated humanoid bet — but the $39B mark prices a fleet that, on the public record, is still a pilot; WATCHING for the BMW-pilot-to-multi-customer-scale proof that converts the story into a tradeable S-1. | — | 1 |
| A real ag-distribution disruptor that just admitted the hard part — the Oct-2025 GCS spin-off makes FBN an asset-light marketplace whose thesis now lives or dies on take-rate and lending, not on owning crop-protection inventory; an eventual IPO is a story, not a date, and the entry round you'd actually clear is a flat-to-down one. | — | 1 |
| The unglamorous AI-optics toll-collector — a 12%-gross-margin Thai contract manufacturer the market is now paying a 45× fabless multiple for; the business is genuinely inflecting (DCI +90%, 1.6T capacity doubling) but the price has front-run two years of execution AND ignores that co-packaged optics is a 2027+ structural axe over the whole pluggable-transceiver thesis. | — | 1 |
| A pure-play T&D wires monopoly that is the lowest-beta, highest-quality way to be long the AI/data-center load boom inside PJM — but the multiple is held ~2 turns below peers by genuine Illinois (ICC) regulatory risk, and the EPS only compounds if the $41B+ capital plan clears its rate cases. Own it for the 9-11% regulated total return, not for a re-rating. | — | 8 |
| "Not investable — absorbed into CZ Biohub (non-profit) Nov-2025 as an acqui-hire; the science is frontier-grade but the equity is gone. The IPO path is dead; track the people (Rives) and the ESM model line, not the cap table." | — | 8 |
| A de-risked pure-wires utility trading at a ~15x discount because Connecticut's regulator and FERC keep clipping its allowed returns — re-rates only if the CT "constructive shift" is real and the FERC ROE appeal claws back basis points; the AI-power bid does not apply here. | — | 8 |
| A well-run, growing mid-cap copper producer that has just turned the corner on Tucumã and deleveraged to 1x — but it is a single-country (Brazil), copper-price-levered, no-yield growth story already trading near analyst targets after an 83% run, so the easy money has been made; own it as a high-beta copper call (Furnas optionality + grade recovery), not as a value entry. | — | 8 |
| The interconnection monopoly the AI bears mis-modeled — Hindenburg's accounting case is legally dead, recurring revenue is re-accelerating into the AI inference build-out, and the 24.6x forward AFFO is a fair price for the one data-center asset with a real network-effect moat; the live risk is that AI's center of gravity sits in wholesale, where EQIX is structurally light. | — | 1 |
E Equillium, Inc.catalyst in 43d | A two-asset preclinical option on EQ504 (gut-restricted AhR modulator for UC) wrapped in a >3yr cash runway and tier-1 (RA Capital / Decheng) sponsorship — but at ~$130–185M EV the market is paying real money for a drug no human has yet taken; the entire thesis lives or dies on the mid-2026 Phase 1 PoM readout ~early 2027. | — | 26 |
| A real zinc-battery business is finally being born inside a financial engine that mints non-cash "profits" while burning ~$120M/quarter in cash and diluting holders 49% a year — own the inflection only if you believe COGS crosses below revenue before the Cerberus-and-convert capital structure swallows the equity. | — | 1 |
| The cheapest, highest-margin way to own the 800G/1.6T AI-interconnect ramp — but it is a no-CIK Chinese A-share whose 47% margins, 96% offshore revenue and ~52x P/E all rest on a Broadcom-DSP / Lumentum-EML leash it doesn't own and a hyperscaler order book it can't diversify. | — | 1 |
| A genuinely differentiated TechBio — the only AI-drug-discovery name whose first human readout (ENV-294 oral, 85% EASI off-drug) looks like a clinical event rather than a platform demo; but it is a 9-patient open-label dataset on a $1B mark, so the bet is "does the molecular-glue mechanism replicate in a controlled Phase 2," not "is the AI real." | — | 8 |
| A microinverter monopoly-economics business being repriced as an "AI-power" growth story while its core market is in a policy-driven cliff — the hardware/cash flow is real, the data-center narrative is a call option the multiple already pays for. Net NEUTRAL/WATCHING: own the violent rerating only on proof the 45X cash engine survives FEOC and the non-residential mix actually scales. | — | 8 |
| A pre-commercial silicon-anode battery story trading at ~$1.6B on $32M of lumpy Korean-defense revenue — the entire thesis is one flagship smartphone qualification that keeps slipping; brilliant architecture and an A-list mobile CEO, but until a real OEM ships, this is a binary, dilution-exposed option, not a business. | — | 1 |
| A 20-year serial cash-burner with a real PLC fab and a going-concern stamp, re-skinned as a CPO/AI-optics pure-play — the FR8 order is genuine but the balance sheet, not the technology, decides this stock. | — | 1 |
| "EMX no longer exists as a standalone — it was absorbed into Tether-controlled Elemental Royalty (ELE) in Nov-2025; the only tradeable expression is ELE, a fast-growing mid-tier gold royalty whose central, non-diversifiable risk is that a stablecoin issuer owns 51% and runs the board." | — | 8 |
| The most-cited consumer-EEG brand in research, now repricing itself as "cognitive AI infrastructure" — but 23 years in, ~$10M ever raised, and a Chilean supreme-court delete order make it the BCI category's pioneer that capital forgot, not its winner. WATCHING — a be-early IPO-readiness name, not yet investable. | — | 0 |
| A finished portfolio transformation now priced as a secular AI-power growth story (~22x FY26 adj. EPS) on a balance sheet that earns ~12% ROE — quality is real, the re-rating has front-run it; WATCHING for a pullback to the low-$120s or an orders stumble. | — | 8 |
| A real, revenue-generating cloud-lab platform with a genuine moat (encoded protocols + installed instrument base), now strategically squeezed between a frozen-since-2019 cap table and a 2025-26 wave of "AI scientist" entrants who raised 2-4x ECL's lifetime total in a single round — own the infrastructure thesis, but ECL is the incumbent at risk of being out-capitalised, not the obvious winner. | — | 8 |
| The purest listed pick-and-shovel on the AI datacenter electrification build-out — net-cash, 28% ROE, record $15.6B backlog — but the easy re-rate is done; at ~26x forward EPS you are now paying full price for a cyclical contractor whose margin and backlog both sit at all-time highs. | — | 1 |
| The best operating asset in pharma trading at a price that already imputes a $150B+ obesity TAM — own it on the franchise and the orforglipron/retatrutide optionality, but size for a multiple that compresses from ~30x forward as the price war and TAM-skeptic camp grind on the narrative. | — | 1 |
| A pre-revenue, going-concern junior building North America's only cobalt-sulfate refinery into the best cobalt tape in 4 years — fully funded to first metal (Q4 2027) with a binding LGES offtake, but the equity is a perpetually-diluting option whose intrinsic value the creditor-controlled cap table keeps confiscating; own the cobalt thesis here only if you can stomach a Jervois-style wipeout and the ATM grinding you down to commissioning. | — | 8 |
| The only eVTOL on Earth that is certified AND sells aircraft at 61% gross margin — but it's a China-only, VIE-wrapped, $465M micro-cap whose order book a short-seller called fake, whose Q1'26 deliveries collapsed 64% YoY, and whose own 20-F admits the "backlog" doesn't obligate anyone to buy. Real revenue, fake-able demand. WATCHING, not yet investable. | — | 8 |
| A foundational-CRISPR IP estate wrapped around a single, late-arriving preclinical asset (EDIT-401) — a binary 2026-2027 LDLR bet that is years behind Lilly/Verve, now fully funded into 2027+ by a May 2026 raise that diluted holders ~25%; the moat is real, the pipeline is not yet. | — | 1 |
| A high-quality regulated wire utility (10% authorized ROE, 7% rate-base CAGR, no equity dilution to 2030) trading at a ~12.5x forward core P/E — a ~30% discount to the 18x peer group — entirely because of one un-estimable variable: the Eaton Fire bill. The stock is not a utility, it is a binary option on whether SB 254's $21B Wildfire Fund + the $4.3B Liability Cap actually hold when the CPUC tests them for the first time in 2027. | — | 8 |
| Not a space stock and barely an operating company — a spectrum-liquidation special-sit where the FCC forced Charlie Ergen to sell ~$43B of dead spectrum into AT&T/SpaceX, converting a going-concern into ~$10B+ net cash plus a SpaceX equity stake; the 10x off the 2025 lows already prices the rescue, so the remaining edge is deal-close certainty + the marked-to-IPO SpaceX stake, not the melting Pay-TV/Boost core. | — | 8 |
| Best-in-class electrical compounder with a genuine data-center order inflection (Electrical Americas backlog +44%, organic orders +42%), but the market is paying ~31x forward / ~28x EV-EBITDA for it while Eaton just levered up to ~$20B net debt and paid 22.5x for Boyd Thermal at the exact moment hyperscaler-capex doubt (DeepSeek, AI-capex margin test) became the dominant de-rating risk — own the business, respect the entry price; WATCHING for a hyperscaler-capex air-pocket or a margin-beat that proves tariff pass-through. | — | 8 |
| The best-positioned "Intel-inside" of gene therapy — an AI-designed AAV-capsid arms dealer with five pharma majors paying milestones+royalties and the first two commercial capsid licenses (Roche CNS, Astellas muscle) already exercised — but it is selling the picks-and-shovels into a sector that is actively imploding (Sarepta deaths, FDA pulled the AAV platform designation, Biogen/Pfizer/Vertex/Takeda all exited), its own lead CNS mechanism (TfR) just killed a child in a rival's (Capsida's) trial, and it has not raised priced equity since its 2021 $500M-post Series A — so the whole bet rides on whether better-engineered delivery is the thing that *saves* AAV or just a sharper tool for a category the market has already started to abandon. | — | 8 |
| A bond proxy that quietly turned into an AI-load growth stock — the cheapest large-cap regulated utility (18.9x) is being handed the largest capex plan in the industry ($103B) and a 4.5GW data-center backlog, but the entire re-rate hinges on a hostile North Carolina commission letting it earn on that base. | — | 1 |
| A de-risked regulated growth utility hiding inside a decade-long value-trap reputation — the Loudoun County data-center boom is the largest demand tailwind in US utilities, but the equity only re-rates once CVOW finishes clean and the dividend finally grows; until then you are paid ~3.9% to wait on a BBB+ balance sheet stretched by a $65B capex plan. | — | 0 |
| Best-engineered enzymatic-DNA-synthesis platform with a tier-1 crossover cap table — but ~4 years since its last equity raise, a founder-out / outside-operator reset, and a razor-and-blades instrument fighting Twist's column-scale economics make this a WATCHING name, not a buy; the IPO window stays shut until it proves an installed base and recurring-reagent pull, and a down-round (or strategic sale) is the more likely next print than an S-1. | — | 8 |
| A real, broad-based analog/discrete cyclical recovery (5 straight quarters of double-digit growth) onto which the market has bolted a ~2x re-rate to ~38x fwd P/E — earnings are inflecting up, but the stock now prices the 40% gross-margin dream as if it already arrived; the asymmetry is bearish-into-strength, not bullish. | — | 8 |
| The AI-era landlord with the cleanest balance sheet it has had in a decade — but the moat is durable, the price already pays for it; an own-the-toll-road BULLISH at a watch-on-pullback price, not a fat-pitch entry. | — | 1 |
| A AUD-cash machine bolted to ONE iron-ore tonnage stream that has just stopped growing — the dividend is safe, the growth narrative (lithium) is real but 2+ years and one commodity cycle away; rerate needs an iron-ore price it doesn't control. | — | 8 |
| A single-asset uranium developer whose ~US$2.8B cap already pays ~2.6x the Phoenix after-tax NPV — it is a leveraged bet on first-of-a-kind ISR + freeze-wall working AND uranium staying >$80; de-risked on permits, NOT on technology. | — | 8 |
| First-ever blood-brain-barrier biologic just got approved (AVLAYAH, Mar 2026) — Denali is now a de-risked platform with a small rare-disease revenue base, but the May LUMA Parkinson's failure gutted the biggest pipeline call option, so you're paying $3.3B for a ~$525M-peak orphan drug plus optionality the market just learned to distrust. | — | 1 |
| A real, durable AI-infrastructure winner trading like one — the growth is unimpeachable but the margin (mid-single-digit AI op-margin) and the AP-funded working-capital engine mean the bull case is now priced; WATCHING for a memory-cost or AP-normalization air-pocket to get paid. | — | 8 |
| A levered Solana proxy whose only value-creation engine — issuing stock above NAV to buy SOL — has stalled exactly as mNAV collapsed to ~1.0x; below par the flywheel runs in reverse and the $83M Q1 equity wipeout, three material weaknesses, and a SOL-collateralized margin book make this a forced-deleveraging short into the next SOL drawdown. | — | 1 |
| Best-in-class ag-equipment compounder at the bottom of a brutal large-ag cycle, already re-rated to ~32x on a trough-earnings recovery — the moat and the precision-ag option are real, but the price has front-run the recovery, so this is a high-quality WATCH, not a fresh entry. | — | 1 |
| The lab that broke the cost-of-intelligence narrative and now anchors China's sovereign AI stack — a frontier-class open-weight model trailing the closed leaders by 3-6 months at ~1/50th the unit cost, but state-captured, un-investable to US capital, and monetizing almost none of the value it creates. | — | 1 |
| Best-in-class compounder mid-cycle — bioprocessing orders are inflecting (+30% YoY) just as the multiple has de-rated ~22% on Masimo-deal scepticism; the cycle turn is the asset, the $9.9B patient-monitoring detour is the risk. | — | 8 |
| A freshly-amputated pure US tower REIT trading at a peer-premium AFFO multiple it no longer earns — leaderless (interim CEO #2 in two years), no organic growth until ~2027, with a $3.5B DISH claim in court and a one-time $7B deleveraging that masks a structurally lower growth ceiling than AMT. WATCHING; the re-rating is a 2027 story, not a 2026 one. | — | 8 |
| A genuinely strategic Western heavy-rare-earth asset wrapped in a serial-promoter, pre-revenue, dilution-machine equity — the deposit is real, the metallurgy and the 2029 cash-flow date are not yet, and the stock already prices a permitting+offtake fairy-tale at ~$1.5B with $0 revenue; WATCHING, would only own on a proven-metallurgy or fully-funded BFS catalyst. | — | 8 |
| The only commercial CRISPR company is a Vertex-controlled 40% royalty stub bolted to a self-funded in-vivo pipeline — own it for CTX310/zugo-cel optionality, not for Casgevy, whose cell-collection bottleneck caps the near-term cash story. | — | 1 |
| A real moat in AEC reliability and an n-1 cost edge, riding a verticalizing AI-interconnect ramp — but ~84% of revenue sits in three hyperscalers and ~41x forward earnings already prices in the optical pivot working. Bullish business, expensive stock; conviction gated on customer diversification proving out. | — | 1 |
| The cleanest pure-SaaS bet in AI protein engineering — Google-pedigreed, wet-lab-backed, already billing 6 of the top-25 pharma — but it has deliberately disarmed itself of the one thing that creates equity value in this field (it owns no molecule, takes no royalty, signs no IP), so it is selling a fast-commoditizing copilot whose best customers (Novo Nordisk) are simultaneously funding the open-source models that erode its moat. | — | 8 |
| A wide-moat seed/chem duopolist priced for steady compounding, sitting on a triple inflection — royalty flip to net out-licensor, the Bayer settlement unlocking corn/cotton licensing, and a 2H26 split that hands the clean-growth Seed business to SpinCo and dumps every legacy liability on Crop-Protection-Co; own the seeds, scrutinize the chem. | — | 1 |
| The only European bidirectional-BCI in US human trials, backed by the BioNTech family office (Santo/Strüngmann) — a Breakthrough-Device, stroke-rehab-first asset that is structurally early and structurally under-capitalised; WATCHING for the funding round that proves the Strüngmanns will write a BioNTech-scale cheque, not just an option. | — | 0 |
| Real AI-optical winner with a genuine fusion/fiber moat and an early-beat Springboard, but the stock has been re-rated to ~46x forward / ~11x EV-sales on a hyperscaler-concentrated capex bet — the business is BULLISH, the price is priced-for-perfection; WATCHING for a multiple reset, not chasing $212. | — | 8 |
C CoreWeavecatalyst in 44d | The story got bigger AND riskier since Jun 14. RPO leapt $60.7B→$99.4B and the cost of capital genuinely improved (first IG-rated HPC debt, A-, <6%); but net loss widened to $(740)M, capex guidance jumped to $31–35B, ~$8.5B of fresh 8.5–9.75% debt was raised post-quarter, and the prior "regulatory: clean" call is WRONG — multiple securities-fraud class actions are now live over concealed data-center delays. Still a leveraged bet on the AI-capex cycle wearing an infrastructure costume; fairly-to-richly priced at ~$96 (EV ~$86B). WATCH; the de-risking (IG debt, <30% non-IG backlog) is real but does not change direction — want a cheaper entry or a GAAP/FCF inflection before paying up. | — | 8 |
| A bitcoin miner that became an AI-datacenter landlord — the shareholders who killed CoreWeave's $9B buyout were right, and CoreWeave then handed them a $10.2B / 590 MW lease as consolation. The bet is now binary on one tenant. Bullish on execution, but it is a single-customer levered real-estate play priced like a software compounder (~20x sales) — own the buildings, fear the concentration. | — | 8 |
| The cheapest dominant company in the world — a 40%-share, 27%-ROE compounder priced at ~22x because it carries a Chinese-passport discount and a US-blacklist overhang the market refuses to underwrite away; bullish, but the re-rate needs a geopolitical thaw that may never come. | — | 1 |
| The best nuclear asset base in America, now bolted to a gas fleet and priced as an AI-power call — at ~26x forward the upside is no longer in the price for free, and the Dec-2025 FERC co-location order is the binary the bulls are underweighting. | — | 1 |
| A flawless, fully-regulated NYC rate-base compounder priced like one — ~17.5x forward earnings and a 9.4% allowed ROE buy you a bond-proxy 6–7% EPS/dividend grower, not alpha; the asymmetric risk is political (NY rate-hike backlash + gas-ban terminal value), not operational. WATCHING, would own on a yield > ~4% reset. | — | 8 |
| A de-risked computational-discovery option on AstraZeneca's rilvegostomig — the last surviving TIGIT bet — wrapped around a $135M cash shell and a binary 2027 ovarian readout; you are buying the royalty stream and the platform, not COM701. | — | 1 |
| The regulated front-door to crypto with a real moat and a strengthening regulatory tailwind, wrapped around an earnings stream so volatile it just printed back-to-back GAAP losses — a ~70x-NTM-P/E call on crypto cycle timing dressed up as a fintech compounder; own the franchise, not this price. | — | 1 |
C Coherent Corpcatalyst in 42d | An II-VI/Coherent merger debt-mule reborn as the picks-and-shovels supplier of the AI-optics supercycle — backed out to 2028, Nvidia-anchored, and de-risking the balance sheet — but priced at ~49x forward EPS that already embeds flawless CPO execution it has not yet proven. | — | 1 |
| A non-invasive, AR-first AAC headset with a real FDA-Breakthrough wedge and two distribution partners — but at a ~$25–46M valuation after 12 years and ~$25–32M raised, it is a mission-driven research-tools / assistive-device niche player, not a venture-scale BCI bet; the asymmetry is acquisition-by-a-giant, not an IPO. | — | 1 |
| A high-quality, asset-light machine-vision franchise mid-cyclical-recovery (Q1 '26 +21% cc, GM back to 71%, new CEO executing) — but the tape already prices a flawless multi-year re-acceleration at ~34x forward EPS, so the edge is in the cycle, not the multiple. WATCHING, not chasing. | — | 0 |
| A real platform with a lottery ticket attached — the legacy biocatalysis P&L is shrinking and the entire equity is a bet that enzymatic siRNA manufacturing (ECO Synthesis) becomes the standard before the cash runs out in 2027; the 4x off the $0.96 March low has front-run any GMP revenue. | — | 1 |
| A structurally-sound #2 ag-equipment franchise at trough earnings and a 0.84x EV/Sales — but the bull case rests on a 2027 cyclical recovery that tariffs, a self-inflicted precision-tech gap vs Deere, and Brazil credit stress can each defer. WATCHING — own the cycle turn, not the current print. | — | 1 |
| A best-in-class regulated grid-build story (8%+ rate-base CAGR, $25.8B 5-yr capex, ~9 GW data-center pipeline that LOWERS customer rates) trading at a defensible-but-not-cheap ~19x forward P/E — the bull case is sound, but the stock is already a market-rate hold (consensus PT ~$80 vs ~$74), so the edge is timing the data-center contract-signing catalysts, not the multiple. | — | 8 |
| World's #1 cobalt + a top-tier DRC copper grower trading at a deep state-owned/jurisdiction discount (~4-9x P/E vs 12-22x peers) — the value gap is the thesis; the DRC quota regime and Beijing's hand on the till are the reasons it persists. | — | 8 |
| The category-defining digital-ag platform is now a non-core software unit inside a balance-sheet-stressed Bayer that gives it away to sell chemicals — great product, captive owner, no clean way to own it. | — | 1 |
| A leveraged, blast-furnace cyclical printing its worst losses since the acquisition spree — but the tariff-supported price floor is already bending the loss curve up, and the stock has nearly doubled off the low pricing much of that recovery in. Bullish on the operating turn, but the debt + dilution + cash-burn make this a high-beta option, not a compounder. | — | 1 |
| "A leveraged bet that BlackRock/Total keep feeding cheap drop-downs into a 5.5x-levered yieldco while the OBBBA tax-credit cliff slams shut — the 4.8% yield is safe, the 5-8% growth is sponsor-dependent and policy-exposed. Own it for income, not for the AI-power narrative bulls are pricing." | — | 8 |
| A best-in-class US bitcoin miner that has rebuilt itself into a 0%-convert-funded, share-shrinking BTC-beta vehicle now sprinting late into the AI/HPC pivot — the equity is a leveraged call on bitcoin and on executing a datacenter business that today earns exactly $0. | — | 1 |
| The legacy networking incumbent has bought a real AI-infrastructure call option (orders 0→~$9B FY26) for the price of its gross margin — own it for the re-rating that's already half-done, not for a margin story that's structurally going the wrong way. | — | 8 |
| A best-in-class fabless analog compounder priced like a value stock for one reason — ~91% of revenue is Apple, and the Skyworks→Broadcom socket loss is the live proof that an Apple-concentrated supplier can be displaced overnight; 15x forward P/E is the market correctly pricing single-customer risk, not a mispricing. | — | 8 |
| A high-quality, regulation-first stablecoin franchise priced as a fintech but earning like a leveraged bond fund — the entire thesis now hangs on two August 2026 events (the Coinbase renegotiation and the rate path), and at ~$80 the market is paying for a re-rating that requires Circle to win both. | — | 1 |
| A bitcoin miner that has successfully optioned itself into an AI landlord — $11.4B of hyperscaler lease backlog backstopped by Google and Amazon is real, but the equity is priced for flawless execution of a buildout that hasn't started cashing rent, and the whole thesis is a bet on shovels-in-the-ground beating the sector's 25%-delivered track record. | — | 1 |
| Real AI-optical winner caught at a euphoric, deeply cyclical top — the business inflected for real (FY26 rev +32% to $6.3B, adj op-margin ~19% vs a 4.8% FY24 trough), but at ~70x forward / ~10x EV/sales the stock is pricing permanence onto a name whose own 5-year record is 14.5%→4.8% margin and a -49.5% drawdown. BULLISH business, BEARISH-into-strength the entry. WATCH for the cycle to breathe. | — | 8 |
| A pre-revenue gene-editing ag-biotech whose science and regulatory thesis are largely vindicated — yet the equity is a serial-dilution / going-concern liquidation race where the $234.9M related-party royalty liability and a balance sheet that is 72% goodwill mean even a successful 2027 Rice launch may accrue mostly to insiders and the next financing, not to today's common holder. WATCHING, not investable, until a non-dilutive partner cheque or a strategic-alternatives outcome lands. | — | 8 |
| The world's largest rare-earth producer is a state policy instrument, not a shareholder vehicle — at P/E ~66 / ~$25B cap on ~7% ROE you are paying a growth multiple for a margin that its own parent (Baogang) taxes away one concentrate hike at a time. Own the NdPr theme through a price-taker, not this price-maker-that-isn't. | — | 8 |
| A high-quality, low-growth toll-bridge on drug R&D whose most profitable segment (NHP-based safety testing) is being slowly disrupted by the very FDA roadmap it just spent $507M vertically integrating against — a 2026 "earnings stabilise + Elliott returns capital" trade, not a growth compounder; structurally WATCHING, tactically NEUTRAL near $213. | — | 8 |
| The single most exciting private name in AI-bio — Chai-2/3 is the first AI antibody platform with a wet-lab-validated, repeatedly-improving hit rate AND signed pharma revenue (Lilly + Pfizer); the bet is whether a portable, lab-light software platform can defend value capture against Isomorphic's deeper engine and the platform-vs-asset value trap. WATCHING for an IPO that is 2-3 years away. | — | 8 |
| A real, regulator-embedded biosimulation moat trading like a broken SaaS roll-up — but the bet only works if the new CEO can re-accelerate software past the +7% Q1 stall before the M&A floor (SLP at 2.5x) is the only thing holding the stock. | — | 1 |
| The shelf RE-GROUNDS and partly CORRECTS the prior web-only read. Three filings-level facts reshape the thesis. (1) Concentration is NOT "OpenAI is the new whale" — as of the reported period the top two customers are MBZUAI (62% of FY25 revenue / 77.9% of AR) and G42 (24%), BOTH UAE-affiliated related parties = 86% of FY25 revenue; OpenAI is a forward 750MW contract (deploys 2026-2028) whose revenue has barely begun. (2) FY25 GAAP "net income $237.8M" is an accounting artifact of +$390.7M of non-operating Other income — dominated by a one-time $363.3M non-cash gain on extinguishment of the Series F forward-contract liability — while operations LOST $145.9M and non-GAAP net loss was $(75.7)M. (3) The margin guide-down is substantially a *reported-revenue* effect (customer-warrant amortization that reduces revenue + datacenter pass-through booked gross + rent-back start-up costs), per management a 10-15pt transitional drag, not purely "inference is structurally low-margin." Net: real wafer-scale architectural edge, genuinely circular AI-infra financing now on the balance sheet (~$1.0B OpenAI working-capital loan at 6% + OpenAI & AWS customer warrants), still UAE-concentrated revenue, ~46x FY26-guide sales vs CoreWeave at ~7x. WATCHING, bear-leaning on valuation; the structural short case is weaker than the prior dossier asserted and the *transitional-margin* read is more defensible. | — | 8 |
| The single most tariff- and operationally-levered way to own a structurally walled-off US aluminum price — a high-beta, low-EV/EBITDA call levered to a record Midwest premium, gated by a Glencore-controlled cap table, a Jamalco material weakness, and a hedge book bleeding against its own thesis. | — | 1 |
| The only U.S.-owned enrichment platform with an NRC HALEU license and a $900M DOE expansion award — but it is still a sub-scale fuel broker living on a Russian supply contract that dies in 2028, priced at 50–60x earnings for a build-out that is contingent on money it does not yet have. | — | 1 |
| A high-quality, all-regulated Houston-load-growth compounder whose 8% EPS algo is real and trackable — but at ~23x forward / a clear premium to integrated peers, the market is already paying for the data-center boom while the Beryl/$800M-generator reputational and regulatory tail stays un-discounted. Quality name, full price — WATCHING for a multiple reset or a clean regulatory all-clear. | — | 8 |
| Not a robotics name — the purest large-cap pick-and-shovel on AI back-end networking (800G→1.6T switches + custom hyperscaler racks), compounding adjusted EPS ~45%/yr; but ~65% of revenue sits in three hyperscalers and the stock already prices ~37x forward, so the bet is "does hyperscaler capex and Celestica's share survive a single-customer wobble" rather than "is there demand." | — | 1 |
| Path-to-tradeable already resolved — Marvell bought Celestial for $3.25B upfront (+$2.25B earnout) and closed Feb 2, 2026; the only way to own this thesis is MRVL, and the bet is whether photonic scale-up I/O hits a $1B run-rate by FY29 or stalls at a science-fair demo. | — | 1 |
| A great cyclical wearing an AI-infrastructure costume — the power-gen backlog and 3x engine capacity build are real, but at ~37x forward earnings and a price above the street's own target, the market is paying secular-compounder multiples for a tariff-squeezed, dealer-inventory-flattered late-cycle machine. WATCHING, not chasing. | — | 8 |
| An $44M-EV option on allogeneic CAR-T — the market prices the pipeline at zero while the durability data quietly de-risked; the bet is binary on ANTLER-3 financing, not on the science. | — | 8 |
| "Real, accelerating transplant-dx franchise that just turned GAAP-profitable and is reshaping itself (sell low-margin kits, buy oncology MRD) — but ~46% of its core segment still rides on a single Medicare LCD that CMS has confirmed it will re-issue; a quality compounder priced for the good case with a binary policy fuse attached. WATCHING, leaning constructive, gated on the new LCD." | — | 8 |
| The clear commercial leader in laser weeding with a real data flywheel and a fresh CFO-led pre-IPO posture — but penned into the narrow, cyclical specialty-crop niche with a ~$370M-marked-up-to-~$550M valuation that already prices the broadacre dream it has not yet earned. WATCHING, not buying, until the AutoTractor RaaS line and a credible row-crop path prove the TAM is bigger than vegetables. | — | 1 |
| A leveraged, pure-play Americas copper call trading at a mid-tier P/NAV discount — own it for the deficit and the MV-Optimized/Santo Domingo growth stack, but the entry price is now a bet that record copper holds, not that the assets are cheap. | — | 8 |
| A Bitmain/Antalpha-controlled reverse-merger shell wearing a Bitcoin-miner costume and now an AI-compute costume — high-cost fleet, ~50% related-party voting control, a NYSE sub-$1 delisting clock, and a balance sheet half-built on Antalpha loans; avoid the equity, watch only as a Bitmain-proxy / forced-restructuring special situation. | — | 1 |
| World's #2 nickel reserve at first-quartile cost with state backing — but a US$2.5bn funding gap on a ~C$400m shell means the entire bet is binary on the 2026 financing close, not the geology. | — | 8 |
C Canaancatalyst in 43d | A real #3 ASIC maker that just clawed back to gross profit and product parity with Bitmain — but it is a sub-$1 going-concern call masquerading as a turnaround, where serial equity dilution and a hashprice depression decide the outcome long before the A16 does. | — | 1 |
| The pure-play AOI/metrology pick on the HBM-and-chiplet inspection supercycle — >40% HBM-inspection share and 50% of revenue now AI-driven — but a ~50x forward multiple already prices the boom while 49% China revenue sits under a tightening export-control gun. | — | 0 |
| The best-in-class Western uranium franchise with a free option on a nuclear-construction renaissance — but the market already owns it at ~35x forward EV/EBITDA and ~50x earnings, pricing the Westinghouse $80B build-out and a structural uranium deficit as near-certainties when the asset is operationally fragile (chronic mine shortfalls) and Westinghouse still loses money at the net line. Great company, demanding price; WATCHING for a multiple reset or an operational/contracting catalyst. | — | 8 |
| Alphabet's $2.5B/12-year longevity moonshot just lost its only pharma partner — AbbVie walked after the lead asset flopped — and the surviving thesis is now a 3-asset rare-disease biotech (ADPKD antibody the crown jewel) wearing an aging-research halo; not a 2026 tradeable, watch the ADPKD Phase 2 readout as the sole de-risking event. | — | 1 |
| A toll-booth on the AI-silicon boom with 86% gross margins and an $8B backlog — but priced for perfection at ~42x forward earnings while the agentic-AI upsell that justifies the multiple is not yet in the model and a fresh DOJ guilty plea caps the China optionality. Quality is not the question; the entry price is. | — | 8 |
| The world's lowest-cost EV/battery manufacturer is now margin-bleeding in a brutal domestic price war it helped start; the entire bull case has migrated to a high-margin export ramp that tariffs and a Brazil/Hungary regulatory cloud are built to throttle — cheap on forward P/E only if you trust earnings that GMT says are flattered by ~¥300B of supply-chain-financed hidden debt. | — | 1 |
| The only North American sole-source maker of naval reactor cores plus the first US microreactor — a genuine monopoly franchise compounding off a record $8.65B backlog, but the tape has already paid ~43x forward earnings for that quality, so the entire bull case from here is multiple-defense, not business risk. | — | 1 |
| A genuine semiconductor moat wrapped around a sub-scale, still-unprofitable medtech — the Midjourney/Embedded licensing pivot is real and re-rates the story, but at ~10x forward sales with episodic licensing revenue and a founder selling, the price already imputes the platform it has not yet proven. | — | 1 |
| A real top-5 institutional spot venue trapped inside a confusing IFRS gross-up and a $2.8B crypto treasury that turns every quarter into a BTC-price referendum — now betting the company on a $4.2B Equiniti/tokenization pivot. Watch, not own, until the Equiniti deal closes and adjusted-EBITDA durability is proven through a full crypto down-cycle. | — | 8 |
| A high-quality scientific-instruments franchise that bought its way into spatial-biology/diagnostics at the top, then watched the core decelerate (organic -3.7% FY25, -4.4% Q1'26) and margins collapse (GAAP OM 14.7%→2.0% in two years) under tariffs, FX and integration drag — leveraged ~6.75x net-debt/EBITDA with a fresh 6.375% preferred ahead of common, now trading ABOVE the median analyst target. WATCHING/BEARISH-tilt until organic growth re-inflects and the $100-120M cost program proves margins can recover; the bull is a 2027 self-help re-rate, the bear is that "Project Accelerate" was empire-building that permanently lowered through-cycle ROIC. | — | 8 |
| The only at-scale, FDA-cleared, revenue-bearing non-invasive BCI franchise heading to a public listing — but it is a Chinese military-civil-fusion controversy with a confidential HK IPO, no public financials, and a US national-security cloud, so it is un-investable on a US/UK book until it trades and discloses. | — | 1 |
| The most physically capable humanoid in the world, wholly bankrolled by its own customer (Hyundai) — which is exactly why the standalone economics are unprovable until a third party pays full price in 2027. | — | 1 |
| A best-in-class integrated Nordic miner-smelter whose precious-metal-rich, e-scrap-fed smelter chain is the rare structural winner of the negative-TC era — but at ~21x P/E and a price above the average analyst target, the stock already prices the gold-silver windfall, not the smelter-margin reset risk and post-fire/post-acquisition execution debt. | — | 8 |
| A real #2 to SpaceX with anchor demand and a flight-proven heavy lifter — but a single-pad, single-stage company that just lost its only launch site and its only customer's confidence in the same month, forced into its first outside raise at the exact moment SpaceX vacuums up the capital. | — | 1 |
| A real business finally inflected to GAAP profit on the AI-power boom — but the stock is priced as if the 2.8 GW Oracle deal is the floor, not the ceiling; the asymmetry now runs short. | — | 1 |
| A payments compounder mid-turn — Cash App user growth is dead but Dorsey's 40%-headcount AI cut converts a flat top line into ~700bps of margin expansion and ~60% adj-EPS growth; the bet is on durable efficiency + on-balance-sheet lending working, against an AML/credit overhang. BULLISH/MEDIUM at ~16x forward. | — | 8 |
| The most-implanted BCI on Earth and the worst-capitalized relative to its peers — a 2008-era electrode bet now owned by a stablecoin issuer, where the moat is two decades of human data and the kill-switch is glial scar tissue. Watching, not buying, until a De Novo/PMA submission and a clean secondary mark say the Tether money actually bought commercialization rather than just runway. | — | 1 |
| The toll-booth on the financialization of everything — ETFs, private markets, Aladdin, and now tokenized + crypto rails — trading at ~19x forward for low-double-digit organic-fee compounding; the bull case is "BlackRock IS the market," the bear case is that the market has finally noticed and is suing over it. | — | 0 |
| "The best-run pure-play crypto asset manager and the clear altcoin-ETP first-mover (BSOL, BHYP) — but its revenue is a levered call on crypto AUM into a falling tape (BTC −18.5% MTD June 2026), and a fee-compression vise is closing on the one product line that still pays. Own the franchise; respect the cyclicality. Watch for an S-1, not a thesis-defining one yet." | — | 8 |
| A leveraged Ethereum proxy that lives and dies on the mNAV premium — and the premium is already gone (trading ~0.75–0.89x NAV), turning the equity-issuance flywheel into a dilution headwind on a $9–10B ETH bet audited by a two-person Nevada CPA shop. | — | 1 |
| The world's pickaxe monopoly is structurally un-investable in the West — a ~$15-19B private ASIC cartel-leader whose moat (TSMC leading-edge access + 35-40% Antminer share) is being deliberately severed by US national-security policy (Operation Red Sunset, Sophgo Entity List, the GAIN Act), not by a competitor. Bet on the franchise, fear the flag. | — | 8 |
| "A 0.21%-gross-margin trading book wearing a custody trust's clothing — the real recurring engine (~$190M of fees) is genuine and compounding, but the headline $16B revenue, a bitcoin-treasury P&L whipsaw, controlled-company governance, and a live IPO-disclosure class action mean BTGO at sub-$11 is a 'show me the fee growth, ignore the topline' watch, not yet a buy." | — | 8 |
| A bitcoin miner that has bet the company on becoming an AI-datacenter landlord — ~$3.5B market cap, ~$800M of dry powder, a 2.2GW shell pipeline, and ZERO signed leases. Pure optionality priced as a near-certainty; the stock is a binary on three hyperscaler signatures landing before YE2026. | — | 8 |
| A vertically integrated Bitcoin miner pretending to be an AI infrastructure play — it scaled hash rate 8x straight into a 50% BTC drawdown (Q1-26 gross LOSS), is funded mostly by its own CEO's related party (BIT Group), and is being sued for the exact SEAL04 chip story the bulls are paying for. WATCHING; the AI pivot is real-but-tiny (~$69M ARR vs IREN's billions in signed contracts) and the equity is a levered BTC call dressed as a compute story. | — | 8 |
| A pre-close SPAC (still trading as CEPO at ~NAV) that wants to be "Strategy with a put-selling desk" — Adam Back's 30,021-BTC vehicle is being born at the exact moment the entire treasury-company premium engine (mNAV) has collapsed below 1.0 sector-wide, and its whole reason to exist evaporates if it can't trade above the bitcoin it holds. | — | 8 |
| Already an announced cash-merger — TECH is a ~$2 (≈2.8%) merger-arb spread to Merck KGaA's $73 all-cash offer, not a fundamentals trade; own the spread only if you'll size the ~$15+/share antitrust/China deal-break to the high-$50s and accept the lawsuit-driven volatility. | — | 8 |
| A ~$3B operating stub trading inside a holding company whose $5B Sartorius stake is the whole story — Elliott just made the sum-of-the-parts discount the trade, not the shrinking life-science tools business. | — | 8 |
| A €17bn cash fortress wrapped around a melting COVID annuity and one make-or-break fast-follower oncology bet (pumitamig) — the founders just announced they're walking out the door, and the market still pays a premium for a pipeline that is, so far, the second-best PD-(L)1×VEGF in the world. | — | 1 |
| A real ag-biologicals franchise (Rizobacter) trapped inside an over-levered Cayman holdco in going-concern doubt — creditors are credit-bidding the US crown jewels for cents, $222M of debt matures in FY2026 against $14M cash, and the equity at $0.42 is a near-worthless option on a restructuring, not an investment in the science. | — | 1 |
| A burned-then-reborn aging-biology platform whose entire ~$730M cap now rests on one Phase 1 asset (oral brain-penetrant NLRP3 inhibitor BGE-102) printing best-in-class hsCRP — fully funded to 2029, but the value-creating Phase 2 readouts are still 6-18 months out and a Lilly-backed competitor (ex-Ventyx) is the same molecule class with deeper pockets. | — | 1 |
| The largest and most profitable money machine in crypto, run by pardoned founders behind a co-CEO compliance veneer — own the BNB-token flywheel, not the unpriceable, politically-leveraged equity; the EU exit and headquarters-less perimeter are the live cracks bulls keep waving away. | — | 8 |
| A real lab-in-the-loop antibody-engineering shop with blue-chip pharma validation (AbbVie/Lilly/Merck/Amgen) and now its own clinic-bound ADC — but it is dramatically out-capitalized ($145M vs. $1B+ peers) and is becoming a Lilly satellite; WATCHING as a private, with the IND-into-clinic 2026 prints as the only catalyst that re-rates it. | — | 8 |
| A debt-free clinical biotech trading below net cash after the FDA rejected its lead's trial design — the platform and a 4-year runway are free, but only if the EphA2/radioconjugate pivot proves the machine can make a second winner. | — | 1 |
| A copper compounder still priced as an iron-ore proxy — the re-rate is real but gated on iron ore not breaking before copper volumes arrive (2028+), and Jansen's serial cost blowouts are the tell that BHP's build muscle has atrophied. | — | 8 |
| A $2B SPAC zero — the tech was real, the business model never was; the only live residual is the IP estate now inside privately-held Confluence Genetics, not a tradeable Benson Hill. | — | 1 |
| "The platform pioneered AI drug discovery and was real; the public-market vehicle and the unit economics were not — a £1.5bn SPAC that destroyed ~96% of value and was taken private by its founders at a ~€40-57m carcass. UNINVESTABLE as a public name (delisted); WATCH only as a private/strategic-acquisition tell for the ai-bio thesis. The lesson, not the ticker, is the asset." | — | 8 |
| The base-editing platform with the cleanest in-vivo clinical proof-of-concept yet (BEAM-302 corrected a disease-causing mutation in living patients) and a near-term commercial shot (risto-cel BLA by YE26) — a genuine BULLISH-but-binary genomics name where the science de-risked faster than the commercial model. | — | 1 |
| The only AI-bio company building a proprietary, legally-clean training dataset 100x deeper than UniProt — own the data layer of TechBio and it is a generational compounder; if foundation labs (ESM, AlphaFold) reach "good enough" on public data first, it is a beautifully-sourced commodity. Watch for an EDEN-derived therapeutic deal with real economics and a priced Series C. | — | 8 |
| A sum-of-the-parts re-rating story trading as a melting ad stock — the structurally-shrinking search cash cow is being replaced in real time by AI Cloud (+79% infra) and a global #1-by-volume robotaxi, but the market won't pay for the option until the legacy ad bleed stops dragging the consolidated line; the Q1-2026 return to +2% growth and the RMB16.2B Core write-down marks the pivot, not the peak risk. | — | 8 |
| The purest public-market-bound bet on optical I/O — strategically anchored by Nvidia + AMD + TSMC, but priced at $3.75B into a thesis (third-party CPO chiplets inside the GPU package) that its own anchor investors are simultaneously building in-house. | — | 1 |
| A real, scarce, China-gated InP asset that AI-optics demand made strategic — but the stock already priced an ~80x melt-up to a ~$5.9B cap on an $88M-revenue, loss-making, single-country-manufacturing base; the asset is genuine, the multiple is a dare. | — | 1 |
| The softest neural interface on the planet with zero chronic human data — a genuine materials-science lead wrapped around an unproven clinical thesis and a behind-the-pack regulatory position; a WATCH, not a bet, until a Fleuron probe records cleanly past 90 days in a living brain. | — | 1 |
A | The only European-sovereign launch prime AND a newly-minted NATO solid-rocket-motor merchant supplier — structurally cheap on sales, structurally expensive on earnings; the entire bull case is a margin-expansion bet (~6% EBITDA today) that does not arrive until Avio digests in-house Vega-C economics + the US SRM ramp post-2028. Buy the franchise, not the 2026 print. | — | 8 |
| A self-help margin re-rating priced as a doomed smelter — the $0 TC/RC tape masks that Aurubis already earns more from downstream premiums, recycling and a finished $1.7B capex cycle than from the concentrate spread the bears fixate on; watching, not yet a buy, because the metal-price tailwind that lifted FY25/26 guidance twice is the same lever that breaks on a copper pullback. | — | 0 |
| The best-run pure-play gas LDC compounding rate base ~14%/yr behind a fully-tracked recovery machine — but the NTSB just named its own leak-management program the probable cause of two fatal Mississippi explosions, and the stock already prices the growth at ~20x with a thin 2.25% yield. Quality is real; the entry is not cheap and the safety overhang is a live, uncapped tail. | — | 8 |
| A pre-revenue option on owning the only direct-to-unmodified-phone cellular layer in space — FCC-blessed and ~$4.5B-funded through ~90 satellites, but the entire bull case is a single binary that resolves in 2027: can it manufacture, launch, and switch on a 45–60 satellite constellation before Starlink's good-enough text/voice layer makes "broadband from space" a feature nobody pays a premium for. At ~$31B on $71M of 2025 revenue, the market is already paying for flawless execution it has not yet seen. | — | 1 |
| A genuine technical first (the only firm to fly-around non-cooperative debris) wrapped in a pre-revenue cash-burning balance sheet trading at ~31x sales — the science works, the commercial P&L is a 2028+ promise, and the stock just halved because the promise slipped a year. | — | 8 |
| A genuine post-COVID turnaround now firing on operating leverage (Q1 op margin 11.8%, book-to-bill 1.26, $734M record backlog) — but the stock already 3x'd to a ~64x trailing / ~27x forward P/E that prices the recovery as permanent, leaving thin margin of safety with a levered balance sheet and a live Lufthansa patent overhang. | — | 8 |
| A genuine pick-and-shovel monopoly on PCIe-Gen6 datacenter connectivity, growing 90%+ with 76% gross margins — but priced at ~26x forward sales with one customer (AWS) at ~70% of revenue; the moat is real, the price is the bet. | — | 1 |
A ASP Isotopescatalyst in 43d | A pre-revenue isotope-enrichment story trading on three real Western-monopoly catalysts (Yb-176, Si-28, HALEU) — but the FY25 "revenue" was construction it has since deconsolidated, the GAAP loss is a $124M convertible-note mark, and the tape is a 22%-short battleground stuck in active securities-fraud litigation. The science could be a generational supply-chain unlock; the accounting and promotion are exactly what shorts say they are. WATCHING, not yet ownable. | — | 1 |
| The one company AI cannot route around — a literal EUV monopoly compounding at mid-teens with a fortress balance sheet, priced at ~55x for perfection while the only real bear (a China DUV ban naming ASML in statute) caps the downside at ~5% of revenue. Own the moat; respect the multiple. | — | 1 |
| A platform-validated RNAi engine the Street prices as a partnering machine, not a commercial one — the entire bull case is whether plozasiran's sHTG sNDA (YE2026) turns a $15.2B milestone option-stack into owned product P&L before the 15% PIK debt and serial dilution grind down the equity. | — | 1 |
| A profitable-at-the-EBITDA-line, 100%-domestic-content solar-tracker #2 trading at half Nextracker's multiple — but the equity is a thin slice trapped beneath $400M of compounding 6.25%→cash preferred, a collapsed Brazil segment, and a 2026 OBBB safe-harbor cliff that turns its record order book into a coin-flip on timing. | — | 1 |
| A genuine architectural toll-road compounding at 20%+ with a real second engine (Armv9/CSS rate expansion + first-party AGI CPU) — but priced for a decade of flawless execution (~180x GAAP / ~200x non-GAAP P/E, Street mean ~38% below spot) just as it picks a channel-conflict fight with its own licensees and loses the Qualcomm weapon that defined its moat. BULLISH business, BEARISH price — WATCHING for a multiple reset. | — | 1 |
| The best-run pure-play in AI/cloud Ethernet — but it is priced for perfection (~46x fwd EPS) just as Nvidia's bundled Spectrum-X attacks its richest back-end AI sockets and two customers still drive 42% of revenue. Own the business, respect the multiple; the bear thread is real, not a strawman. | — | 0 |
| A 38-year, $1.7B-NPV NdPr asset that the equity market is pricing as a serial dilution machine — the call is on financing-close + China's price floor, not the ore body. WATCHING into FID-completion; the project is fundable, the share count is the bear case. | — | 0 |
| The credible #2 Western humanoid — NASA-pedigree hardware + Google DeepMind's brain + the Mercedes/GXO/Jabil go-to-market — but priced for a labor-replacement future it has not yet shipped, into a market where Unitree is collapsing the price floor from below. | — | 1 |
| A real but sub-scale optical-transceiver share-gainer whose AI-data-center inflection is genuine — but the equity is priced as if it has already won a market that InnoLight, Coherent and Lumentum actually own, while it funds the build with relentless dilution and parks three-quarters of its receivables on one distributor (Digicomm) on stretched terms. The 2017 Amazon-loss crash is the template, not the exception. | — | 1 |
A Applied Materialscatalyst in 44d | The cheapest of the four equipment leaders riding a re-accelerating AI/GAA WFE upcycle — but the entry is a 4x-off-the-low all-time high, and the bet is whether the >30% 2026 equipment-growth guide is the new floor or a cycle peak being paid for in advance. | — | 1 |
| A compounding life-safety roll-up with a genuine recurring-revenue flywheel and a top-tier capital-allocation board — but at ~20x EBITDA / ~25x earnings, ~53% of the balance sheet in goodwill+intangibles, and a thesis fully dependent on Becker's M&A machine never missing, the quality is real and mostly priced. WATCHING; buy the air-pocket, don't chase the print. | — | 8 |
| A best-in-class, Luksic-controlled Chilean copper pure-play priced for the 30% volume ramp it has not yet delivered — own the asset, not this multiple; the entry is a copper-price dip or a Centinela-2 commissioning wobble, not 14x EV/EBITDA on a name that just missed guidance again. | — | 0 |
| The best business in AI on every metric that isn't valuation — enterprise-led, multi-cloud, ~$30B+ run-rate doubling on weeks — wrapped in a ~$965B mark that already prices a decade of flawless execution and rests on a circular ring of vendor-investors funding ~$180B of compute the company hasn't yet earned the margins to pay for. WATCHING, bull on the business / bear on the entry price. | — | 1 |
| The credible enzymatic-DNA-synthesis survivor — a real fidelity moat (1,005-base record, 50 kb clonal, ~99.9% stepwise yield) now distributed through Danaher/IDT — but it is a sub-$25M-revenue tools shop selling a faster picks-and-shovels commodity into a brutal synbio funding winter; WATCHING as a private until an IPO path or an IDT buyout crystallizes the value. | — | 0 |
| A copper pure-play being born inside an iron-ore company — own the re-rate that completes when Anglo Teck closes, not the diversified miner that's disappearing. | — | 0 |
| The only federally-chartered crypto bank — a genuine regulatory moat priced as a premium IPO candidate, but custody is a fee-compressing commodity where it is the AUC laggard (sub-$50B vs Coinbase's 80%+ ETF share), and a live Homeland Security AML probe is the single fact that can break the whole "trust" thesis. WATCHING into the 2027 IPO; the charter is real, the economics are not yet proven. | — | 8 |
| A best-in-class analog compounder mid-way through a violent cyclical recovery — the business is pristine, the cycle is real, but at ~35x forward / ~65x trailing the tape has already paid for the upturn; the edge is in the next destock, not at today's price. | — | 0 |
| A 20-year, ~$1.7B-deficit cautionary tale of synbio that hit the same wall every fermentation pure-play hits (scale-up economics never closed the gap to chemistry), capped by an SEC revenue-recognition charge and a Chapter 11 that wiped equity to zero — the emerged "Amyris 2.0" is a smaller, Doerr-controlled private with no public equity to buy and no edge proven; AVOID / un-investable, watch only as the canonical synbio-failure comp. | — | 8 |
| A real, first-mover aviation/drone battery franchise inflecting to its first profitable year — but priced at ~17x guided 2026 sales with a China related-party supplier (Berzelius, ~36% of COGS, tied to the founder) now the subject of an active short report; the franchise is bullish, the stock is a show-me on revenue quality. | — | 1 |
| A 90-year connector compounder that the market has re-rated into an AI-infrastructure growth stock — the business is exceptional and the AI cycle is real, but at ~34x forward EPS and 50% above its own decade-average multiple, the price already pays Amphenol to keep printing 30%+ organic growth, leaving no cushion if hyperscaler capex normalizes. | — | 1 |
| The indispensable US-soil advanced-packaging chokepoint, priced for a 2030 it has not yet built — ~38x forward earnings on a single-digit-margin, Apple-dependent business about to burn ~$1.5–2B of free cash on Arizona. Great asset, demanding entry; WATCHING for a cheaper door. | — | 8 |
| A levered dividend-compounder running a patent-cliff relay race — the legacy book (>40% of revenue under biosimilar/IRA attack) is being out-sprinted by Repatha/rare-disease/oncology launches, but the equity is priced for MariTide to win the obesity prize it most likely places, not wins, in. | — | 1 |
| A three-engine critical-materials conglomerate whose 2025–26 earnings are flattered by a transient antimony windfall while its real long-duration call options (European LiOH at Bitterfeld, spent-catalyst vanadium recycling, the Saudi Supercenter) are still pre-cash-flow — own the structural story, but underwrite the cycle, not the print. | — | 1 |
| A global tower REIT mid-reset — DISH churn masks 4-5% organic + a CoreSite AI option the market half-ignores; quality compounding at a fair (not cheap) ~17x EV/EBITDA, with leverage and a 2026 "AFFO growth floor" the swing factors. BULLISH-leaning WATCH; conviction unlocks if 2027 reaccelerates as guided. | — | 8 |
| A regulated transmission monopoly that has accidentally become an AI-infrastructure pure-play — 63 GW of mostly-hyperscaler load (≈80%, 20-year take-or-pay) underwrites a $78B/5yr plan and a hard 7–9% EPS CAGR; the bet is regulatory-execution and balance-sheet, not demand. BULLISH/MEDIUM around $128, the rare utility where the growth is contracted, not hoped-for. | — | 8 |
A American Bitcoincatalyst in 43d | A Trump-branded, Hut-8-controlled bitcoin-accumulation SPV that sells equity to buy BTC and rents its mining from its parent — a ~3x-mNAV levered BTC proxy with no AI optionality, now down ~94% and asking holders for a 1-for-40 reverse split. | — | 1 |
| A best-in-class regulated growth utility whose 6–8% EPS CAGR is now under-written by real, contracted data-center load (2.2 GW signed) and ~10.6% rate-base growth — but the market already pays 20x for it, the FCF is structurally negative, and the entire thesis rides on Missouri and Illinois regulators staying constructive. | — | 0 |
| A genuine edge-AI vision SoC franchise finally inflecting to growth and operating leverage — but it is still GAAP-unprofitable, ~70% revenue routes through one distributor, and the stock prices both a re-acceleration AND an unresolved M&A bid. Quality asset, demanding price, binary catalyst. | — | 1 |
| The neutral arms-dealer of the AI build-out — AWS + Trainium + a stake in both OpenAI and Anthropic is the best-positioned compute franchise on Earth, but free cash flow has been incinerated to ~$1B and a ~$200B 2026 capex bet on 5-year-depreciated silicon is the whole thesis. | — | 1 |
| The best-funded biotech ever, reorganizing toward AI after four years and zero disclosed clinical assets — a platform bet whose lead rivals just beat it into the clinic; WATCHING, not ownable, until a named program and a runway figure exist. | — | 1 |
| A single-asset MASH/AUD/ALD bet on a glucagon/GLP-1 dual agonist that wins on liver biology and lean-mass-sparing but loses on raw weight loss — fully funded into 2028 with a binary AUD readout in Q3 2026 as the next free option; a derisked, heavily-shorted optionality vehicle, not a fundamentals compounder. | — | 1 |
| The highest-grade tin mine on earth, throwing off >$600M annualised EBITDA at a 6.7x P/E — and it sits 180km from an active M23 front line in the eastern DRC, now 56%-owned by Abu Dhabi. The discount is the country, not the company; you are paid ~6.5% to wait, but a single security headline can halve it overnight. | — | 1 |
| The market spent two years pricing Alphabet as the AI loser; FY2025 (+15% op income, Cloud margin to 24%, Gemini at 750M users, the antitrust gun mostly de-cocked) proves it owns the full stack — but at $4.5T and a fresh $90B+ capex habit, the easy re-rating is now behind it and the bar is "monetize the buildout." | — | 1 |
| The first RNAi company to scale to profitability — Amvuttra's ATTR-CM launch turned a 20-year science project into a >$5B-revenue franchise inflecting at +71% guided; the bet is whether durable TTR leadership + a 40-program pipeline justify ~70x forward earnings before nucresiran fixes the Sanofi royalty drag. | — | 1 |
| A binary supply-shock proxy — the only Western-aligned tungsten scale producer ramping into a 550%-China-driven price spike, but priced at ~150x trailing sales on a single-mine ramp; own the commodity thesis, not this multiple — a quarter of Sangdong slippage or one China de-escalation re-rates it 40%+. | — | 1 |
| A well-run, deleveraging precision-motion roll-up whose ~0.8% organic growth has been lapped by a +99% / 12-month stock that now trades at ~67x P/E and ~24x EV/EBITDA — the SAME EBITDA multiple as Ametek at 1/20th the scale and quality, and ~20-45% above every published analyst target. Quality business, dislocated price. WATCHING / lean BEARISH on valuation, not on the company. | — | 8 |
| A clean, de-risked regulated-utility compounder where ~3.4 GW of contracted data-center load underwrites a $13.4B / 12% rate-base plan — but at ~22-24x forward P/E and ~$76.66 (already at consensus target), the data-center optionality is fully priced; the edge is a regulatory-lag / financing-cost stumble, not a re-rating. | — | 8 |
| A real, recovering analog franchise (TMR current-sensing + auto/data-center) trading like a hyperscaler — the business is fixed, the stock is not cheap, and a ~32% Sanken overhang still wants out. | — | 0 |
| A genuinely deleveraged, vertically-integrated aluminum pure-play whose 2025-26 earnings recovery is being borrowed from a tariff — ~60% of US aluminum volume rides a Section-232-inflated Midwest premium that is a policy decision away from evaporating; own the cycle, not the multiple. | — | 1 |
| ALB is a high-quality, low-cost lithium asset wearing the price tag of a leveraged call option on the lithium spot price — own the resources, not the P&L; the stock is the commodity in a cyclical costume. | — | 1 |
| The only humanoid actually billing paying customers for real warehouse work — but it is being squeezed between Figure's $39B AI-narrative capital and Unitree's $16K Chinese hardware, and SoftBank already tried to buy the whole thing for under $1B. | — | 1 |
| A high-quality, recurring-revenue lab-tools compounder whose cyclical trough is over and whose margins are inflecting — but at ~20x forward EPS the recovery is already largely priced; the asymmetry is a beat-and-raise grind, not a re-rating. | — | 8 |
A | A cycle-trough, Europe-funded margin story trading at a deserved peer discount — own it for the 2026-27 ag recovery and the PTx self-help, but the entire thesis rests on EME holding up while North America bleeds tariff dollars and PTx Trimble proves it isn't a $2B impairment-in-waiting. | — | 1 |
| A genuine FMCW technology lead and a watershed exclusive-OEM win, priced at ~28x forward sales against ~24 months of runway and a 2028 start-of-production — the technology is real, the chasm between here and revenue is the trade. | — | 1 |
| "World's #1 industrial-PC franchise (ROIC ~29%, net cash, 91% payout) genuinely re-rating into a physical-AI edge-compute play — but the tape has fully paid for it: ~37x trailing / 30x forward and ~3x its own peers, with the moat being distribution/longevity, not silicon. Great business, priced-for-perfection stock. WATCHING, not chasing." | — | 8 |
| The number-two AI compute franchise is finally real (DC $16.6B FY25, MI450/OpenAI 6GW signed) — but at ~58x forward EPS with 320M warrant shares of dilution overhang and an analyst PT below spot, the stock has already priced the win. WATCHING, not chasing. | — | 1 |
| A China-domestic wafer-cleaning champion wearing a US ticker and a US growth-stock multiple — 99.6% China revenue, both operating subsidiaries on the BIS Entity List, margins compressing and FCF negative, yet priced at ~61x forward GAAP EPS. The business is real; the valuation is a different security from the fundamentals. | — | 8 |
| The only Western "mine-to-magnet" pure-play levered specifically to HEAVY rare earths (Dy/Tb) — whose ex-China prices have ~doubled in 2026 (Dy ~US$930/kg, Tb ~US$4,028/kg) — via China's own low-cost ionic-clay geology; but it is a pre-revenue developer that has already re-rated ~5x to a ~CA$1.1B cap, owns a Chilean asset 99% of the local community voted against, faces MP Materials commissioning its own US HREE separation by mid-2026, and must fund a >US$1.5B integrated build off a ~US$40M cash balance with no binding offtake. Asymmetric optionality, not yet a position. | — | 1 |
A Accuraycatalyst in 42d | A distressed sub-$50M-cap #3 in a radiotherapy duopoly — operating losses, a 15% RIF, withdrawn guidance, ~23M warrants of dilution overhang and a stock at $0.26 — where the entire equity is a levered option on a China-JV-and-EMEA recovery the company admits it cannot time; structurally cheap (0.4x EV/sales) but for cause, and not investable until book-to-bill and FCF inflect. | — | 8 |
| A genuine top-4 global optical-component IDM riding the AI interconnect wave — but it is the low-margin generalist (~8% net) trading at a specialist multiple after a 5x run, with consensus targets implying ~55% downside. Real franchise, priced for a margin structure it has never earned. | — | 1 |
A Abscicatalyst in 41d | A re-rated single-asset AI-antibody story — ABS-101's half-life miss quietly killed the old lead, so the entire ~$1.15B cap now rides on one binary (ABS-201 alopecia interim PoC, H2 2026) against a 26%-of-float short and an 18-month runway. Own the readout, not the platform. | — | 1 |
| A de-risked, cash-rich option on one binary — ABCL635 Phase 2 hot-flash data in Q3 2026 — wrapped around a platform whose old royalty engine has gone to zero; the antibody-vs-pill differentiation is plausible but unproven, and at ~$1.5B the market is already paying for a win. | — | 1 |
| A negative-EV ($-60M) clinical-stage AAV play where the market prices the entire pipeline below cash — fully funded into 2H 2028 with two binary Phase 3 wet-AMD readouts (4FRONT-1 1H'27, 4FRONT-2 2H'27) standing between it and either a re-rate or a wipeout; best-in-class intravitreal tolerability is the edge, durability-vs-Eylea-HD/faricimab is the kill switch. | — | 1 |
| A genuine engineering bet (tendon-driven safe humanoid + in-home data flywheel) wrapped in a marketing fiction — NEO ships "autonomous" but runs on stranger-in-a-VR-headset teleop, and the company most likely to make it work, OpenAI, just became its competitor. | — | 1 |
| A real consumables-led inflection (Q1 product rev +9%, 70% GM, FCF-positive) is fighting a settlement-inflated optical decline and a +73% YTD melt-up — the business is turning but the price already pays for the turn; WATCHING into the Atera-vs-installed-base cannibalization quarter. | — | 8 |